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Abstract 
 
Epstein-Barr virus (EBV), a member of the human herpes virus family, encodes 44 micro 
RNAs (miRNAs). Several reports demonstrated their pro-proliferative and anti-apoptotic 
functions, but very few cellular targets of viral miRNAs are known and the physiological 
functions of these miRNAs are largely elusive.  
To identify important target genes of EBV-encoded miRNAs, I infected primary human B 
lymphocytes and systematically studied the effects of the viral miRNAs in the cells early 
after infection. Transcriptome and protein analyses of EBV-infected B cells showed that 
viral miRNAs down-regulated not only pro-apoptotic genes like PMAIP1, as expected, but 
also genes with dedicated functions in immunity including cytokines such as IL-12 and IL-6, 
MHC molecules, several co-stimulatory receptors, and B cell signaling-related genes like Fc 
receptors. Using luciferase reporter assays, I found that EBV miRNAs could directly repress 
the PMAIP1 gene and IL12B, a gene coding for a subunit of the IL-12 cytokine, via their 3’-
UTRs. In particular, multiple EBV miRNAs target IL12B suggesting that viral miRNAs 
regulate certain cellular transcripts robustly, redundantly, and perhaps cooperatively.  
As EBV miRNAs appeared to control a multitude of immune-regulatory genes, I 
investigated several immunological phenotypes. Reduced IL-12 secretion led to a 
suppression of Th1 differentiation in co-culture assays with EBV-infected B cells, indicating 
an immune evasive function of viral miRNAs. Moreover, EBV miRNAs down-regulated 
antigen presentation by MHC class II and interfered with CD4+ effector T cell responses 
including IFN-γ secretion and cytotoxicity. Taken together, EBV-encoded miRNAs globally 
disrupt multiple functions of the adaptive immune system early after infection and thus 
protect EBV-infected B cells from antiviral immune responses of the human host. 
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Introduction 
Human microRNAs 
MicroRNAs (miRNAs) are small RNA molecules of ~22 nucleotides in length (Bartel, 
2004). Generally, miRNAs such as hsa-miR-155 originate from dedicated miRNA genes 
whereas other miRNAs stem from introns of protein-encoding transcripts or snoRNAs (Ha 
and Kim, 2014). Transcribed RNAs are processed by Drosha RNase to short-hairpin RNAs 
(“primary miRNA”) in the nucleus, are transported to the cytosol, processed by Dicer RNase 
to double-stranded RNAs (“pre-mature miRNA”), and form complexes, termed RNA-
Induced Silencing Complex (RISC), as single-stranded RNAs (“mature miRNA”) with other 
proteins like Argonaute (Bartel, 2004). Human cells encode four different Argonaute genes 
(AGO1 to AGO4). The gene products of the AGO genes all bind to miRNA molecules 
without a clear preference (Landthaler et al., 2008). Among them, AGO2 is the only member 
of the AGO family with an endonuclease activity (“Slicer” activity) and directly cleaves 
bound mRNAs (Ha and Kim, 2014). RISCs, which contain miRNAs mainly bind to the 3’-
UTRs of target mRNAs depending on the complementarity between miRNAs and mRNAs 
(Bartel, 2009; Agarwal et al., 2015). Binding to RISC represses translation followed by 
mRNA degradation in most cases (Djuranovic et al., 2012; Selbach et al., 2008). One of the 
mechanisms that causes the translational repression prior to mRNA degradation is the 
localization of RISC-mRNA to P-bodies, which results in the isolation of mRNAs from the 
translational machinery (Fig. 1; Liu et al., 2005a; 2005b). 
There are several features unique to the gene regulatory mechanism of miRNAs: (i) since 
target recognition by miRNAs canonically depends on 6 to 8 nucleotides in the miRNAs (the 
“seed” sequence; Agarwal et al., 2015), a single miRNA species can potentially target 
hundreds of mRNAs simultaneously (Bartel, 2004); (ii) the repressive strength of miRNAs is 
limited compared with conventional transcriptional factors and termed the “fine-tuning” 
ability of miRNAs (Sevignani et al., 2006; Selbach et al., 2008); (iii) in the minority of cases, 
miRNAs down-regulate genes at protein but not at transcript levels (Fig. 1; Selbach et al., 
2008); (iv) a single miRNA occupies very little genomic space such that multiple miRNAs 
often form clusters in the human genome. For example, the mir-17-92 cluster contains six 
independent miRNAs in a single transcript, hence miRNAs in this cluster will be expressed 
at the same time in a polycistronic manner (Olive et al., 2013). 
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The significance of miRNAs has become apparent during the last decade and it is now 
well accepted that they mediate important functions in cells of all vertebrates regulating and 
fine-tuning many cellular processes including development, tumorigenesis, and immune 
responses (Schickel et al., 2008; Xiao and Rajewsky, 2009). 
 
EBV-encoded miRNAs  
miRNAs encoded by herpes viruses are reported to play important roles in cell 
proliferation, development, immune regulation, and other processes in infected cells 
(Grundhoff and Sullivan, 2011; Skalsky and Cullen, 2010). Epstein-Barr Virus (EBV) was 
found to encode a total of 44 mature miRNAs (Fig. 2; Cai et al., 2006; Pfeffer et al., 2005; 
Qiu et al., 2011), which, even among herpes viruses, is a very high number. The functions of 
these miRNAs encoded by EBV (EBV-encoded miRNAs or EBV miRNAs) have been mostly 
elusive because these miRNAs do not bear similarities to miRNAs of other herpes viruses or 
Accelerated deadenylation also results in a reduced 
abundance of miRNA-repressed mRNAs in mammalian 
cells56. Moreover, knockdown experiments in C. elegans77, 
and analysis of the decay intermediates originating from 
repressed mRNAs in worms77 and mammalian cells56,82, 
support the role of decapping and 5? 3? exonucleolytic 
act vities n these systems.
Widespread miRNA-mediated deadenylation 
of mRNAs occurs during zebrafish embryogenesis. 
The miRNA miR-430 facilitates the removal of hundreds 
of maternal mRNAs by inducing their deadenylation and 
s bsequent decay at the onset of zygotic transcription79. 
Interestingly, some miR-430 targets, such as nanos1 and 
tudor-like tdrd7 mRNAs, are repressed by miR-430 in 
somatic but not germ cells, indicating that target destabi-
lization and/or repression can be tissue or cell specific95. 
Likewise, mRNA reporters targeted by let-7 miRNA are 
destabilized to different degrees in different mammalian 
cell lines82.
Although many of the mRNAs that are targeted by 
miRNAs undergo substantial destabilization, there are 
also numerous examples of repression at the transla-
tional level, with no or only a minimal effect on mRNA 
decay (Supplementary information S1 (table)). Studies 
using D. melanogaster S2 cells identified some endog-
enous or reporter miRNA targets, for which repression 
could be entirely accounted for by either mRNA 
degradation or translational repression, or by a com-
bination of both processes78,83. It is not known what 
determines whether an mRNA follows the degradation or 
translational-repression pathway. Accessory proteins 
bound to the 3? UTR might be involved, or structural sub-
tleties of imperfect miRNA–mRNA duplexes, particularly 
of their central regions, could be important82,96.
Whether the deadenylation and the ensuing decay 
are primary or secondary to the translational repres-
sion remains unknown. Clearly, the association of 
AGO inste d of eIF4E with the m7G cap would not 
only prevent effective recruitment of ribosomes, but 
would also disrupt the circularization of the mRNA, 
probably rendering the poly(A) tail more vulnerable 
to exonucleolytic degradation. Experiments that have 
been carried out to explore whether deadenylation is 
a primary or secondary event have not proved to be 
conclusive. Reporter mRNAs that are repressed by 
either oligonucleotides that are complementary to the 
AUG codon or the 5? UTR hairpins do not undergo 
deadenylation unless they contain miRNA sites79,80. 
However, it is unlikely that mRNA circularization is 
disrupted by the oligonucleotide or the hairpin, both 
of which act at some distance from the cap. By contrast, 
the disruption could be effected by the miRNP AGO 
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Figure 3 | Possible mechanisms of the microRNA-mediated post-transcriptional gene repression in animal cells. 
Binding of micro-ribonucleoproteins (miRNPs), possibly complexed with accessory factors, to mRNA 3? UTR can induce 
deadenylation and decay of target mRNAs56,78,79,83 (upper left). Alternatively, miRNPs can repress translation initiation  
at either the cap-recognition stage43,44,53–55 or the 60S subunit joining stage57 (bottom left). mRNAs repressed by 
deadenylation or at the translation-initiation stage are moved to P-bodies for either degradation or storage. The 
repression can also occur at post-initiation phases of translation66–68, owing to either slowed elongation or ribosome 
‘drop-off’ (bottom right). Proteolytic cleavage of nascent polypeptides was also proposed as a mechanism of the 
miRNA-induced repression of protein production67 (upper-right). A protease (X) that might be involved in the process 
has not been identified. The 7-methylguanosine cap is represented by a red circle. eIF4E, eukaryotic initiation factor 4E.
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Figure 1 Proposed mechanisms of miRNA-mediat d transl tional gene repr ssion 
miRNA-containing RNA-induced silencing complex (RISC) mainly bind to 3’-UTRs of target mRNAs and 
induce translational repression through various mechanisms. Only the deadenylation of mRNAs leads to 
accelerated degradation f mRNAs, su gesting that the regulation by miRNAs results in the reduction of 
protein levels but not necessarily in the reduction of transcript levels.
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(modified from Filipowitcz et al., 2007)
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of the vertebrate cells (Walz et al., 2009). This situation makes it difficult to deduce the 
physiological functions of EBV miRNAs from better-studied miRNAs. As a counter-example, 
Kaposi sarcoma-associated herpes virus (KSHV) encodes miR-K12-11, which is an 
orthologue of hsa-miR-155 and miR-K12-11 shares the same target transcripts of miR-155 
(Dahlke et al., 2012; Gottwein et al., 2007). 
The majority of EBV-encoded miRNAs is encoded in three main clusters, the BHRF1 
cluster, the BART cluster 1, and the BART cluster 2 (Fig. 2; Barth et al., 2011). An exception 
is a single miR-BART2, which is distantly encoded from any of the three miRNA-encoding 
clusters of EBV. These viral miRNAs are expressed in most EBV-infected B cells but, 
depending on the latency type, the expression levels of the three miRNA-containing 
transcripts may differ (Cai et al., 2006; Qiu et al., 2011). In the early phase after infection, 
total, which we analyzed three to five months post infection
(p.i.).
Steady state levels of selected BHRF-1 and BART miRNAs
in established LCLs
We determined the steady state levels of two BHRF1 (Figure 2A,
B) and five BARTmiRNAs (Figure 2C to G) in the established LCLs
by quantitative real-time stem-loop PCR analyses. As a positive
control, JM LCLwas used, an LCL infected with an uncharacterized
field strain of EBV that expresses all 44 viral miRNAs. The copy
numbers of selected miRNAs per cellular transcriptome were
determined with synthetic miRNA standards as references.
Prototype 2089 EBV-infected LCLs expressed BHRF1 miRNAs
in the range of 8,000–12,000 copies per cell, which exceeded levels
in JM LCL (Figure 2A, B). Expression levels of BHRF1 miRNAs
in +mirBART EBV-infected LCLs were in the same range as in
prototype 2089 EBV-infected LCL. As expected LCLs infected
with DmirBHRF1 and DmiALL EBVs did not express the
functionally deleted miRNAs.
We assessed the expression levels of two BART miRNAs of
prototype 2089 EBV (Figure 2C, D) and three BART miRNAs
absent in this EBV strain (Figure 2E to G). miR-BART1-5p
and miR-BART2-5p were expressed at about 100–500 copies
per cell. The relative low expression of BART miRNAs as
compared to BHRF1 miRNAs is in accordance with the
literature [33 and references therein] and was also observed in
JM LCL cells infected with an uncharacterized field strain of
EBV. LCLs infected with DmirBHRF1 EBV expressed these
BART miRNAs at levels similar to prototype 2089 EBV-
infected LCLs. +mirBART EBV infection mildly increased the
levels of miR-BART1-5p and miR-BART2-5p (Figure 2C, D).
Steady state levels of those miRNAs absent in B95.8-derived
Figure 1. Schematic overview of the construction of miRNA-mutated EBVs. (A) Genomic localization of EBV’s miRNAs in the EBV reference
strain AJ507799. The two miRNA families of EBV originate from two transcripts that fold into 25 pre-miRNAs as indicated by black bars and give rise to
four mature BHRF1 miRNAs and 40 BART miRNAs. (B) Functional ablation of EBV’s miRNAs. Prototype 2089 EBV is based on the prototypic EBV strain
B95.8 [29], which was cloned in E. coli [28]. As compared to the Genbank entry of the hypothetical EBV reference strain AJ507799, the genome of
B95.8 suffers from a deletion and therefore lacks the coding capacity of the majority of the BART miRNAs as indicated. In E. coli, the three pre-miRNA
structures in the BHRF1 locus of prototype 2089 EBV were replaced with computed scrambled sequences (Table 1) to generate a functional BHRF1
miRNA knock-out EBV termed DmirBHRF1 (or p4004). In a subsequent step, the remaining five BART pre-miRNAs were replaced with scrambled
sequences to generate an EBV genome devoid of any miRNAs. This mutant was termed DmirALL (or 4027). The sequence of miR-BART5 is present in
the genome of prototype 2089 EBV but due to the deletion in the parental B95.8 strain the pre-miRNA cannot form the hairpin structure needed for
miR-BART5’s processing by Drosha as indicated (*) in Figure 1B. (C) Construction of a reconstituted EBV mutant encoding 22 BART pre-miRNAs. The
expression cassette p4079, which encodes all pre-miRNAs of the BART locus, was introduced into the BALF1 locus of the prototype 2089 EBV genome
by homologous recombination as indicated. The EBV mutant that carries all BART miRNAs encoded by conventional EBV strains, was termed
+mirBART (or p4080).
doi:10.1371/journal.ppat.1001063.g001
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and 172 nt length and the EBV-miRNAs. This type III latency is also
found in immortalised LCLs which represent the in vitro correlate
of PTLD. Most EBV-positive tumours encompass large inﬁltrates of
lymphocytes, which, however, do not appear to attack the tumour
cells. While EBNA1 in BL cells averts detection by the immune system
by blocking its own processing and MHC-presentation via inhibition
of the proteasome by virtue of its Glycine–Alanine stretch [68], it is
unclear how the cells in type II latency evade immune-recognition
when expressing the membrane antigens LMP1 and LMP2. As EBV-
infected cells shed miRNAs via exosomes [69], it is possible that the
miRNAs encoded by EBV might play a role in the apparent inability
of the immune system to stage an efﬁcient immune response (see
below).
4. Epstein–Barr virus-encoded microRNAs
Epstein–Barr virus was the ﬁrst virus where miRNAs were found
[65]; the presence of miRNAs was subsequently extended to addi-
tional Herpes viruses [70–74]. At present, the Sanger database (http://
www.mirbase.org/index.shtml, Release 16), lists 25 precursors and 44
mature miRNAs: 4 miRNAs are derived from the BHRF1 cluster, the
remainder being encoded by the BART clusters (Fig. 1 and Table 1).
The original report only demonstrated the presence and expression of
5 EBV-precursors and mature miRNAs (ebv-miR-BHRF1-1, BHRF1-2,
BHRF1-3, ebv-miR-BART1 and -BART2.) as the used cell line was
immortalised by the prototype B95.8 strain of EBV. This fully trans-
portation competent virus features a deletion of about 11 kb
encompassing a large part of the BART transcripts that encode most
EBV-miRNAs [66,71,75,76]. Currently the B95.8 virus expresses a total
of 13 listed miRNAs, 4 derived from the BHRF1-cluster, and 9 from
BART-1, -2, -3, -4, and -15. If one assumes that the EBV miRNAs play a
role in transformation, then these results indicate that the set
of 13 miRNAs encoded by the B95.8 virus is sufﬁcient for in vitro
immortalization of B-lymphocytes. It should be noted that B95.8-EBV
also encodes a snoRNA which is processed to a RNA of about 10 nt
length thought to inhibit the expression of the BALF5 polymerase; a
recombinant virus which does not express the snoRNA is fully
transformation competent, though [77].
While the BHRF1 miRNAs are produced from a transcript that
encodes the BHRF1 protein, the BART miRNAs are produced from
various introns that in turn are derived from a large transcript
Fig. 1. Schematic representation of the genomic location of EBVmiRNAs. The top row shows the EBV genes expressed in cells in stage III latency. The blow-ups show the three miRNA
clusters in greater detail. The deletion within the BamHI A fragment of the EBV genome in the B95.8 strain of EBV is indicated. miR-BART2 runs in antisense orientation to the 3'UTR of
the BALF5 DNA polymerase. miR-BART5* is not expressed due to a partial deletion in B95.8 (modiﬁed from Ref. [121]).
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transformation competent, though [77].
While the BHRF1 miRNAs are produced from a transcript that
encodes the BHRF1 protein, the BART miRNAs are produced from
various introns that in turn are derived from a large transcript
Fig. 1. Schematic representation of the genomic location of EBVmiRNAs. The top row shows the EBV genes expressed in cells in stage III latency. The blow-ups show the three miRNA
clusters in greater detail. The deletion within the BamHI A fragment of the EBV genome in the B95.8 strain of EBV is indicated. miR-BART2 runs in antisense orientation to the 3'UTR of
the BALF5 DNA polymerase. miR-BART5* is not expressed due to a partial deletion in B95.8 (modiﬁed from Ref. [121]).
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a d 172 nt length a d the EBV-miRNAs. This type III latency is also
found in immortalised LCLs which represent the in vitro correlate
of PTLD. Most EBV-positive tum urs e compass large inﬁltrates of
lymphocytes, which, however, do not appear to attack the tumour
cells. While EBNA1 in BL cell averts detection by the immune system
by locking its own processing and MHC-presentation via inhibition
of the proteasome by virtue of its Glycine–Alanine stretch [68], it is
unclear how the cells in type II latency evade immune-recognition
when expressing the membrane antigens LMP1 and LMP2. As EBV-
infected cells shed miRNAs via exosomes [69], it is possible that the
miRNAs encoded by EBV might play a role in the apparent i ability
of the immune syste to stag an efﬁcient immune response (see
belo ).
4. Epst in–Barr virus-encoded microRNAs
Epstein–Barr virus was the ﬁrst virus where miRNAs ere found
[65]; th es nce of miRNAs wa subsequently extended to addi-
tional Herpes viruses [70–74]. At pr sent, the Sanger databas (http://
www.mirbase.org/index.shtml, Releas 16), lists 25 precursors and 44
mature miRNAs: 4 miRNAs are derived from the BHRF1 cluster, the
remaind r being enc ded by the BART clusters (Fig. 1 and Table 1).
The original report only demo strated the presence and ex r ssion of
5 EBV-precursors and mature miRNAs (ebv-miR-BHRF1-1, BHRF1-2,
BHRF1-3, ebv-mi -BART1 and -BART2.) as the used cell line was
immortalised by he prototype B95.8 strain of EBV. This fully trans-
portation competent virus features a deletion of bout 11 kb
encompassing a large art of the BART t anscripts that encode most
EBV-miRNAs [66,71,75,76]. Currently the B95.8 virus expresses a total
of 13 listed miRNAs, 4 d rived from the BHRF1-cluster, and 9 from
BART-1, -2, -3, -4, and -15. If ne assumes that the EBV miRNAs play a
rol i ransforma io , then these results indicate that the set
of 13 miRNAs encoded by the B95.8 virus is sufﬁcient for in vitro
immortalization of B-lymphocytes. It s ould be noted t at B95.8-EBV
also encodes a snoRNA which i processed to a RNA of about 10 nt
length thought to inhibit the expre sion of th BALF5 polymerase; a
recombinant vi us which does not express the snoRNA is fully
transformation competent, though [77].
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various introns that in tu n are derived from a larg transcript
Fig. 1. Schematic representation of the genomic location of EBVmiRNAs. The top row shows the EBV genes express d in cells in stage III laten y. The blow-ups show the three miRNA
clusters in greater detail. The deletion within the BamHI A fragment of the EBV genome in the B95.8 strain of EBV is indica ed. miR- ART2 runs in antisense orientat on to the 3'UTR of
the BALF5 DNA polym rase. miR-BART5* is not expressed due to a partial d letion in B95.8 (modiﬁed from Ref. [121]).
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rem inder being encoded by the BART clust rs (Fig. 1 and Table 1).
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immortalised by the prototype B95.8 strain of EBV. This fully tr ns-
portation competent virus fe ures a deletion of abou 11 kb
encompassing a large part of the BART t ansc ipts that encode most
EBV-miRNAs [66,71,75,76]. Curr ntly t e B95.8 virus expresses a total
of 13 listed miRNAs, 4 derived from the BHRF1-cluster, nd 9 from
BART-1, -2, -3, -4, a d -15. If one assumes that the EBV miRNA play
ole in transfo mation, then these re ult indica e tha th s t
of 13 miRNAs encod d by the B95.8 virus is sufﬁcien for in vitro
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also encodes a snoRNA which is pr c sed t a RNA of bout 10 nt
length thought to inhibit he expression of the BALF5 polymera e; a
recombinant virus which does not express the snoRNA i fully
transformation competent, hough [77].
While the BHRF1 miRNAs are produced from a ransc ipt that
encodes the BHRF1 protein, the BART miRNAs are produced from
various introns that in turn are derived from a large t anscr pt
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EBV
field strain
ΔmirALL
(0 miRNAs)
wt/B95.8
(13 miRNAs)
+mirBART
(44 miRNAs)
pCMV
BART Cluster 1 and 2(modified from Barth et al., 2011)
BART Cluster 1 BART Cluster 2BHRF1 Cluster 
BHRF1 Promote BART Promoter B95.8 deletion
BHRF1-3
B F1-1 BHRF1-2 BART3,4,1,15
BART5,16,17,6
BART21,18,7-9,22,10
BART11,12,19,20,13,14
BHRF1 BFLF2 BILF2 BILF1
TR LMP2A, B
LMP1
LMP2A
Bam A fr.EBNA3
A B C EBNA1QpCp Wp EBNA-LP EBNA2EBERs
EBV miRNAs BART2
 
BALF5
Figure 2 Genomic locations of EBV-encoded miRNAs and EBV strains used in this work 
Field strain  of EBV contain 44 matur  miRNAs. miRNAs re ncod d in three clusters (BHRF1 cluster, RT 
cluster 1, BART cluster 2) and in a single locus for miR-BART2. In this work, three EBV strains, ΔmirALL (no 
miRNAs), wt/B95.8 (wt; 13 miRNAs), and +mirBART (44 miRNAs) EBV were used. wt/B95.8 EBV is based on 
the laboratory strain B95.8, which contains a deletion in the BART cluster region. +mirBART EBV was cloned 
to restore the miRNAs within the B95.8 deletion by cloning all the miRNAs of the BART clusters under 
control of the CMV promoter and introducing into wt/B95.8 EBV (Seto et al., 2010). ΔmirALL EBV was 
established by mutating all the miRNA-coding loci such that the corresponding regions of transcripts would 
have no short-hairpin structures, which are necessary to the biogenesis of miRNAs (Seto et al., 2010).
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during the so-called pre-latent phase, all known miRNAs encoded by EBV are expressed 
(Seto et al., 2010). Therefore, it is conceivable that EBV miRNAs implement important 
regulatory functions during the pre-latent phase. 
 
 
Anti-apoptotic and pro-proliferative functions of EBV miRNAs 
Previously, our former colleague Eri Seto and other groups have demonstrated that a 
cluster of EBV miRNAs, the BHRF1 cluster, has significant anti-apoptotic and pro-
proliferative cellular functions early after infection of primary human B cells (Feederle et al., 
2011a; 2011b; Seto et al., 2010). Nevertheless, the genes regulated by miRNAs of the 
BHRF1 cluster that cause these phenotypes are unknown to date (Grundhoff and Sullivan, 
2011). 
Targets of miRNAs encoded by EBV have been studied by several groups in established 
EBV-infected cell lines obtained from biopsies of Nasopharyngeal carcinoma (NPC) and 
Burkitt’s lymphoma (BL), or lymphoblastoid cell lines (LCL) derived from infecting primary B 
lymphocytes with EBV in vitro (Barth et al., 2011; Dölken et al., 2010; Erhard et al., 2013; 
Kuzembayeva et al., 2012; Riley et al., 2012; Skalsky et al., 2012; Vereide et al., 2013). By 
high-throughput target screens using immunoprecipitation in combination with deep 
sequencing, the authors have identified many potential targets of EBV miRNAs including 
pro-apoptotic genes such as BBC3 (Choy et al., 2008) and CASP3 (Vereide et al., 2013). 
None of these reported pro-apoptotic genes, however, were targeted by BHRF1 cluster 
miRNAs (Barth et al., 2011). In addition, the catalogues of predicted targets published by 
different groups have a surprisingly small overlap (Klinke et al., 2014), which includes IPO7, 
a well-established target of ebv-miR-BART3 (Dölken et al., 2010; Kuzembayeva et al., 2012; 
Skalsky et al., 2012; Vereide et al., 2013). The lack of an apparent consensus and the 
inconsistencies in the published literature (Seto et al., 2010) may be due to profound 
differences in gene expression patterns between different, long-term cultivated, and EBV-
infected cell lines that do not reflect the impact of these viral miRNAs.  
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EBV and immune evasion early after infection 
EBV has developed several strategies to fend off antiviral immune responses of the 
infected human host. For example, EBV establishes a latent infection in B cells which 
express only a minimal set of viral genes, a strategy which can be considered as a 
fundamental mechanism of immune evasion (Ressing et al., 2008). EBV also encodes 
several immunoevasins that suppress the presentation of viral antigens in the lytic phase 
during virus synthesis (Hislop et al., 2007; Rowe et al., 2007; Zuo et al., 2009). Moreover, an 
EBV latent membrane protein controls T cell responses directed against latently infected 
cells (Rancan et al., 2015). 
Despite these measures, EBV antigen-specific effector T cells constitute a considerable 
fraction of the memory T-cell repertoire of the latently EBV-infected human host (Hislop et 
al., 2002). Prior to establishing a stable, latent phase, many viral lytic genes are expressed 
for a short period of time in newly infected B cells during the initial, pre-latent phase, which 
lasts seven to ten days (Kalla and Hammerschmidt, 2012). Among such genes, at least two 
immunoevasins of the lytic cycle, BNLF2a and BCRF1 (viral IL-10), are also expressed 
immediately upon B-cell infection (Jochum et al., 2012). BNLF2a and viral IL-10 interfere 
with the recognition of infected cells by EBV-specific effector T cells and natural killer cells, 
respectively, but they are insufficient to abrogate T cell recognition completely (Jochum et 
al., 2012).  
 
 
Viral miRNAs and immune evasion  
In addition to anti-apoptotic functions, EBV miRNAs also reportedly down-regulate 
MICB (Nachmani et al., 2009), CXCL11 (Xia et al., 2008), and NLRP3 (Haneklaus et al., 
2012) and thus interfere with innate immune responses and inflammation. Interestingly, 
MICB, a gene coding for a ligand of the activating receptor NKG2D expressed on T and NK 
cells, is also targeted by miRNAs of KSHV and human cytomegalovirus (Grundhoff and 
Sullivan, 2011; Nachmani et al., 2009). This result suggests that pathways involved in 
immune evasion are common targets of miRNAs encoded by herpes viruses (Grundhoff and 
Sullivan, 2011). For now, the consensus of the field is that viral miRNAs mainly contribute to 
evade innate immune responses. The only known exception is endoplasmic reticulum 
aminopeptidatse 1 or ERAP1, a critical component for appropriate antigen presentation via 
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MHC class I, which was reported to be targeted by a single miRNA in human 
cytomegalovirus (Blum et al., 2013; Cullen, 2013; Stern-Ginossar et al., 2007).  
As discussed in the previous section, the suppression of adaptive immune responses 
early after infection likely contributes to the success of EBV infection. It is therefore possible 
that EBV miRNAs play a role in this regard for two reasons: (i) EBV miRNAs are expressed 
during all stages of infected B cells (Cai et al., 2006; Seto et al., 2010); (ii) miRNAs are non-
immunogenic and are unlikely to provoke antiviral cellular responses because they are 
indistinguishable from human miRNAs. 
 
 
The aim and the design of my research project 
In my doctoral research, I tried to address the following question: “What are the 
physiological functions of EBV miRNAs early after infection?” I used human B lymphocytes 
newly infected with different EBV strains as a model of primary infection, performed high-
throughput screenings, and made phenotypic assessments (Fig. 3). The EBV strains I 
employed differ only in the numbers of miRNAs encoded in their genomes (Fig. 2). This 
model has several advantages and is superior to established latently EBV-infected cell lines 
as discussed above: (i) I can assess the early days after infection, when the pro-proliferative 
and anti-apoptotic functions of viral miRNAs are most apparent; (ii) comparing different EBV 
strains, which differ only in the capacity to express all, certain, or no viral miRNAs, will 
provides me with phenotypes tightly connected to the functions of EBV miRNAs; (iii) the 
primary B cells prepared from different donors are heterogeneous but will reflect the 
spectrum of miRNA-regulated genes beyond the genetic variability of individuals in contrast 
to established cell lines. These advantages will allow me to identify the most important 
physiological targets of EBV miRNAs. 
In my experimental model, I infected primary human B lymphocytes with three EBV 
strains differing in their miRNA content and analysed the transcriptomes of infected cells by 
deep sequencing in the pre-latent phase, five days post infection (Fig. 3). I identified several 
immune regulatory pathways that are affected by EBV miRNAs, but also genes involved in 
preventing cellular apoptosis and regulating the cell cycle as expected from previous 
studies (Feederle et al., 2011a; 2011b; Seto et al., 2010). With several methods, I identified 
certain selected genes with promising and potentially interesting functions. Among the 
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identified genes, I validated IL12B (an important cytokine) and PMAIP1 (a relevant pro-
apoptotic gene) as direct targets of EBV miRNAs. I also found that viral miRNAs down-
regulate key molecules important for T cell interaction and their immune responses against 
EBV-infected B cells. Moreover, EBV miRNAs repressed the secretion of the cytokine IL-12 
from infected B cells, which resulted in the suppression of type 1 helper T cell (Th1) 
differentiation. Viral miRNAs also controlled epitope presentation to CD4+ T cells and 
interfered with the activity of antiviral effector T cells. 
My findings revealed that EBV-encoded miRNAs govern diverse pathways that regulate 
B cell proliferation and survival but also critical functions in adaptive immunity, promoting 
viral immune evasion in the early days of human primary B cells infected with EBV. 
Infection of human B cells with different EBVs (ΔmirALL, wt, and +mirBART EBV)
• Expression profiling of EBV and cellular miRNAs five days post infection (section 1)
Transcriptome analysis of EBV-infected B cells
• RNA-Seq five days post infection (section 2.1)
• Defining miRNA-regulated genes (section 2.2)
Screening for direct targets of EBV miRNAs
• AGO2 RIP-Seq (section 4.1, 4.2)
• 3’-UTR reporter assays (section 4.3, 4.4)
Immunological evaluation of miRNA-regulated genes
• Cytokine profiling (Section 5)
• Helper T cell differentiation assay (section 6)
• Effector T cell activation assay (section 7)
Identification of miRNA-regulated gene categories
• KEGG enrichment analysis (section 2.3, 2.4)
• Protein quantification (section 3)
Figure 3 The strategy to decode physiological functions of EBV-encoded miRNAs 
I conducted experiments with multiple and sequential steps to identify physiologically important targets and 
functions of EBV-encoded miRNAs. Corresponding Result sections are indicated for each step.
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Results 
1. EBV-infected B cells contain substantial amounts of EBV-encoded miRNAs 
five days after infection 
To investigate the alteration in the transcriptome induced by EBV-encoded miRNAs 
early after infection, I infected human primary B cells with three EBVs that differ in the 
number of encoded miRNA. To validate this model of primary infection, I performed miRNA 
transcriptome analyses and profiled the expression of EBV-encoded miRNAs in B cells 
infected with the three different EBV strains. 
 
1.1 Infection of primary B cells with EBV mutants with various numbers of miRNAs 
I infected primary B cells prepared from adenoids of six donors (Ad1 to Ad6) with three 
different EBV mutants (Fig. 2, Fig. 4A): wt EBV is based on B95.8, a widely-used laboratory 
strain of EBV, and contains 13 mature miRNAs (Delecluse et al., 1999); ΔmirALL EBV is 
devoid of any miRNAs (Seto et al., 2010); +mirBART EBV encodes all 44 mature miRNAs 
(Seto et al., 2010) listed in miRBase as of 2014 (Kozomara and Griffiths-Jones, 2011). B95.8 
strain contains a deletion in miRNA-encoding region (Fig. 2) compared with field wild-type 
strains, but I call B95.8-based EBV strain as wt EBV for the consistency to the preceding 
work of Seto et al., 2010. 
Previously, we reported that EBV-encoded miRNAs control apoptosis and activate cell 
cycle progression, two effects that were most apparent five days post infection (Seto et al., 
2010). Therefore, I cultivated B cells newly infected with EBV for five days, and performed 
experiments described in Result section 1.2 and 2 below. 
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Figure 4 EBV-infected B cells contain EBV-encoded miRNAs early after infection 
EBV miRNAs of infected B cells were investigated five days post infection. Primary B cells infected with 
three EBV strains, ΔmirALL (no miRNAs), wt (13 miRNAs), and +mirBART (44 miRNAs) EBV were
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1.2 Relative quantification of EBV-encoded miRNAs in EBV-infected cells 
I performed RNA immunoprecipitation and sequencing (RIP-Seq) experiment with an 
antibody directed against Argonaute2 (AGO2), a core protein of the RISC (RISC; Bartel, 
2004), to measure the amount of each EBV-encoded miRNA as well as human miRNAs (Fig. 
4A). AGO2 is one of four human Argonaute proteins, which bind small RNAs including 
miRNAs (Bartel, 2004; Meister et al., 2004). The resulting RNA fragments of RIP-Seq include 
miRNAs bound to AGO2 and mRNAs captured by RISC (Rüdel et al., 2008). cDNA libraries 
of the immunoprecipitated RNAs were synthesized by a commercial supplier (vertis 
Biotechnologie AG). The following deep sequencing was performed by The University of 
Wisconsin, Biotechnology Center, DNA Sequencing Facility. Jonathan Hoser and 
Maximillian Hastreiter (Helmholtz Center Munich, Institute of Bioinformatics and Systems 
biology) performed the mapping and subsequent bioinformatical analyses.  
In cells infected with wt EBV and +mirBART EBV, 14.53% (±2.41% SD) and 22.37% 
(±6.18% SD) of all miRNAs were of viral origin, respectively (Fig. 5A). In contrast, EBV-
encoded miRNAs were barely detected in B cells infected with ΔmirALL EBV as expected 
indicating that my analysis was not compromised by donor B cells accidentally infected 
with field strains of EBV (Fig. 4B, C).  
 
 
 
 
 
subjected to AGO2 RIP-Seq. EBV-encoded miRNAs were expressed at five days post infection largely as 
expected.

(A) Enrichment of AGO2 by RIP with an anti-AGO2 antibody. Representative western blot detection of AGO2 
after RNA immunoprecipitation (RIP) is shown. 1% of cell lysate, supernatant after RIP, and dynabeads 
conjugated with anti-AGO2 antibodies were used. The anti-AGO2 antibody precipitated the majority of 
AGO2 protein. 
(B)(C) Fractions of each EBV-encoded miRNAs are shown as the mean of six donors ± Standard Deviation 
(SD). All EBV-encoded miRNAs but miR-BART20 were expressed in B cells infected with wt or +mirBART 
EBV. There were almost no EBV-encoded miRNAs in ΔmirALL EBV-infected cells indicating that B cells from 
six donors were not accidentally infected with field strains of EBV. (B) miRNAs encoded in both wt and 
+mirBART EBV (BHRF cluster miRNAs and part of BART cluster miRNAs). (C) miRNAs encoded only in 
+mirBART EBV (a part of BART cluster miRNAs).
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Figure 5 EBV-encoded miRNAs reach sizable fractions of total miRNAs early after infection 
miRNA transcriptomes of infected B cells were investigated five days post infection. Human miRNAs were 
reduced in wt or +mirBART EBV-infected B cells compared with ΔmirALL EBV-infected B cells.

(A) EBV-encoded miRNAs as a fraction of total miRNAs are shown. Means of six donors are presented. 
+mirBART EBV-infected cells encode more EBV-encoded miRNAs than wt EBV. As a result percentages of 
miRNAs reflect the number of viral miRNAs encoded by the two EBV strains. In contrast, almost no EBV 
miRNAs are found in ΔmirALL EBV-infected B cells.

(B) Fractions of the top ten most abundant human miRNAs in infected B cells. As EBV-encoded miRNAs 
increase, the fractions of the top human miRNAs and the rest of human miRNAs decrease. An exception is 
miR-155, which increases in +mirBART EBV-infected B cells. Means of six donors ± SD are shown.
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1.3 Differential expression of hsa-miR-155 in B cells infected with different EBV 
strains 
From the same RIP-Seq data described in Result section 1.2, I investigated the 
alteration of the human miRNA transcriptomes induced by the three different EBV strains 
(Fig. 5A). In B cells infected with wt EBV or +mirBART EBV, the fraction of viral miRNAs 
increased to substantial levels (14.5% vs. 22.4%) while many of the top ten human miRNAs 
decreased. This effect was expected because EBV-encoded miRNA were expressed in 
addition to human miRNAs. 
The exception, however, is one of the most abundant human miRNAs in infected B cells, 
hsa-miR-155, which showed a different expression pattern. The fraction of miR-155 sharply 
declined in wt compared with ΔmirALL EBV-infected B cells (Fig. 5B). Paradoxically, the 
fraction of miR-155 in B cells infected with ΔmirALL and +mirBART EBV were almost 
identical. This observation suggests that viral miRNAs encoded only by +mirBART EBV 
indirectly caused unexpected strong up-regulation of miR-155 (Fig. 5B, Fig. 2).  
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2. EBV miRNAs mainly regulate genes involved in immune regulatory pathways, 
cell proliferation, and the B cell receptor signaling pathway 
I analysed the transcriptomic changes induced by EBV miRNAs comparing mRNA 
transcriptomes obtained by RNA sequencing (RNA-Seq) from ΔmirALL, wt, or +mirBART 
EBV-infected B cells. Since the transcriptomes and effects of viral miRNAs varied 
considerably among the six donors, we employed a fold-change based rank score (see 
Materials & Methods) to define consistently and differentially regulated genes by EBV 
miRNAs. 
 
2.1 Summarization and visualization of the transcriptomic data 
We applied the Primary Component Analysis (PCA) to eighteen samples (six donors 
infected with one of the three EBVs) to measure the variability of mRNA transcriptome data 
among donors and viruses used for infection (Fig. 6). There was no apparent clustering with 
respect to EBV strains or B cell samples prepared from the six donors. This finding 
indicated that the transcriptomes between different donors varied too much for EBV 
miRNAs effects to dominate. 
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Figure 6 Transcriptomes between primary B cells diﬀer substantially among the six donors 
Primary Component Analysis of transcriptomes in six B cells infected with the three EBV strains. First and 
second primary components (PC1 and PC2) of each donor and virus strain were compared. There was no 
clear clustering either by donor or by virus strain indicating that infection with the three diﬀerent viruses did 
not lead to substantially diﬀerent gene expression profiles beyond those of the individual B cells from six 
diﬀerent donors.
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2.2 Comparison of differentially regulated genes 
Different donors infected with the same EBV strain cannot be treated as biological 
replicates due to the individual variations as discussed in Result section 2.1. Therefore, we 
performed donor-wise comparative transcriptome analyses of B cells infected with the 
three different EBVs. From these six pairs of data sets based on the infected B cells 
prepared from six donors, I calculated a fold-change based rank score of each gene, which 
evaluates the consistency and degree of differential expression among all donors (see 
Materials & Methods). Using this score, I sorted the identified genes and selected the most 
strongly and consistently up- or down- regulated genes (Fig. 7A) as candidate targets of 
EBV miRNAs. As a result, 748, 933, or 913 genes out of 44681 genes (Ensembl Annotations 
Release 77), which were expressed in EBV-infected B cells, were selected as top down-
regulated genes comparing “wt vs. ΔmirALL” EBV-infected B cells, “+mirBART vs. ΔmirALL” 
EBV-infected B, or “+mirBART vs. wt” EBV-infected B cells, respectively (Fig. 7A, B).  
From these directly or indirectly miRNA-targeting genes, I tried to identify canonical 
targets of EBV miRNAs, which should locate to the intersections of the three comparisons 
“wt vs. ΔmirALL”, “+mirBART vs. ΔmirALL”, and “+mirBART vs. wt” (Fig. 7B, 
Supplementary Table 1). This is because wt and +mirBART EBV encode 13 and 44 miRNAs, 
respectively, but the 13 miRNA in the wt EBV are part of the 44 miRNAs in +mirBART EBV 
strain (“wt EBV miRNAs”) and only the remaining 31 miRNAs are unique to +mirBART EBV 
(“+mirBART EBV-unique miRNAs”; Fig. 2). Therefore, the 136 genes within the intersection 
of the data sets of “wt vs. ΔmirALL” and “+mirBART vs. ΔmirALL” are considered to be the 
canonical targets of those wt EBV miRNAs (Fig. 7B, Supplementary Table 1). In fact, this 
intersection contained IPO7, a well known target of miR-BART3 (Dölken et al., 2010), which 
is encoded by wt EBV. Similarly, +mirBART EBV-unique miRNAs are supposed to target 
318 genes within the intersection of “+mirBART vs. wt” and “+mirBART vs. ΔmirALL” (Fig. 
7B, Supplementary Table 1). Unexpectedly, LTB is the only gene in the overlap between “wt 
vs. ΔmirALL” and “+mirBART vs. wt” (Fig. 7B), which is down-regulated by miRNAs 
encoded in wt EBV, and is further down-regulated by +mirBART EBV-unique miRNAs. It 
thus appears that 13 miRNAs, which wt and +mirBART EBV share, and 31 miRNAs unique 
in +mirBART EBV mainly regulate different groups of genes.  
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Figure 7 wt EBV miRNAs and +mirBART EBV-unique miRNAs target diﬀerent cellular genes 
Transcriptomes of infected B cells were measured five days post infection. Primary B cells were prepared 
from six diﬀerent donors (Ad1 to Ad6), infected with three EBV strains (ΔmirALL, wt, and +mirBART EBV), 
and subjected to RNA-Seq. miRNAs encoded by wt EBV down-regulated 136 genes including IPO7, a 
known target of an EBV miRNA. +mirBART EBV-unique miRNAs down-regulated 318 genes. Only one gene 
was commonly repressed by miRNAs encoded by both wt and +mirBART EBV-unique miRNAs suggesting 
that the two groups of miRNAs mainly regulate diﬀerent genes.
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2.3 KEGG enrichment analysis of genes regulated by miRNAs in wt EBV-infected B 
cells 
To narrow down the presumed functions of EBV miRNAs in the early phase of infection, 
we analysed the regulation of functional groups of genes according to Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathway categories based on the differentially regulated 
genes discussed in Result section 2.2 (Fig. 8, Supplementary Fig. 1). From the comparison 
of ΔmirALL and wt EBV-infected B cells, I found that miRNAs encoded in wt EBV regulate 
genes involved in immune responses and cell proliferation (Fig. 8A). In line with previous 
findings, pathways linked to apoptosis, cell cycle regulation, and p53 signalling were 
enriched (Feederle et al., 2011b; Seto et al., 2010; Vereide et al., 2013), and known pro-
apoptotic genes (Strasser, 2005) such as BBC3 (PUMA), PMAIP1 (NOXA), and BAX were 
down-regulated at transcript levels (Fig. 8B). Interestingly, regulated pathways included cell 
adhesion molecules (this KEGG category also encompasses co-stimulatory molecules and 
HLAs), TNF signaling, antigen processing and presentation, cytokine-cytokine receptor 
interaction, RIG-I, and Toll-like receptor (TLR) signaling (Fig. 8A). 
Affected transcripts in these pathways included cytokines like IL12B (coding IL-12p40), 
CCL22, or TNF (coding TNF-α), which were among the top candidates of consistently 
down-regulated transcripts in wt compared with ΔmirALL EBV-infected cells (Fig. 6B). This 
finding suggested an anti-inflammatory role of EBV miRNAs early after infection. Similarly, 
transcripts of genes involved in antigen presentation and co-stimulation such as CD80, 
CD274 (PDL1), and CD40 were consistently down-regulated (Fig. 8B). It thus appears that 
wt EBV miRNAs control various target genes that may play important roles in immune 
responses of the infected host directed against EBV-infected primary B cells.  
(A) The sorted heatmap displays top diﬀerentially expressed transcripts (up- and down-regulated) comparing 
wt EBV-infected cells versus ΔmirALL EBV-infected cells, or +mirBART EBV-infected cells versus wt EBV-
infected cells. Selection was based on a fold change rank score and transcripts with |Z-score|>1.6 are 
shown (see Materials & Methods). Transcripts are sorted by the fold change rank score and color-coded 
according to fold changes as indicated.

(B) Overlaps of top down-regulated genes comparing B cells infected with the three EBV strains. The 
numbers of diﬀerentially down-regulated genes (Z>-1.6) and overlaps among them are shown in a pair-wise 
comparison as indicated. 136 genes within the overlap between ”+mirBART vs. ΔmirALL” and “wt vs. 
ΔmirALL” are likely to be canonical targets of wt EBV miRNAs whereas 318 genes within the overlap 
between “+mirBART vs. ΔmirALL” and “+mirBART vs. wt” likely encompass main targets of +mirBART EBV-
unique miRNAs. In line with this observation, IPO7, a well-known target of wt EBV miRNAs, is located in the 
overlap between “+mirBART vs. ΔmirALL” and “wt vs. ΔmirALL”. There was no overlap between “+mirBART 
vs. wt” and “wt vs. ΔmirALL” except one gene (LTB) indicating that the canonical targets of wt EBV miRNAs 
and +mirBART EBV-unique miRNAs are diﬀerent. Several genes in the intersections are shown as examples.
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Figure 8 Viral miRNAs in wt EBV mainly regulate genes involved in immune regulatory pathways and 
cell proliferation 
To deduce the physiological functions of EBV miRNAs, a KEGG pathway enrichment analysis was 
applied with the viral miRNA-regulated genes shown in Fig. 7. I observed that miRNAs of wt EBV regulate 
genes linked to immune regulatory pathways and cell proliferation.
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2.4 KEGG enrichment analysis of genes regulated by miRNAs in +mirBART EBV-
infected B cells 
As in Result section 2.4, I classified targeted genes regulated by +mirBART EBV-unique 
miRNAs according to the KEGG pathway categories (Fig. 9, Supplementary Fig. 2). 
Pathways previously identified in the pair-wise comparison of “wt vs. ΔmirALL” were also 
enriched comparing “+mirBART vs. wt” EBV-infected B cells with high probabilities (Fig. 8A, 
Fig. 9A). This finding suggests that +mirBART EBV-unique miRNAs regulate genes in 
pathways involved in immune responses and cell proliferation as wt EBV miRNAs do. The 
p-values of the enriched categories that stem from the comparison of “+mirBART vs. wt” 
are similar to “wt vs. ΔmirALL”, but the fold changes observed in the latter were generally 
lower (Fig. 8A, Fig. 9A, Supplementary Fig. 1, Supplementary Fig. 2). This tendency may 
reflect the overall low expression of +mirBART EBV-unique miRNAs compared with miRNAs 
encoded in wt EBV (Fig. 4B, C). Considering the fact that the overlap between canonical 
targets of wt EBV miRNAs and +mirBART EBV-unique miRNAs contain just one gene 
(Result section 2.2; Fig. 7B), my results imply that these two classes of miRNAs regulate the 
same pathways but different genes. 
 
  
 
 
 
(A) KEGG enrichment analysis of selected pathways, which are listed according to their significances in 
descending order. The analysis on the basis of the top diﬀerentially regulated genes comparing “wt vs. 
ΔmirALL” EBV-infected B cells is shown. The sizes of the orange dots indicate -log10 p-value scores. For 
two of the six donors, fold change values of diﬀerentially expressed transcripts are mapped and plotted 
together with the linked pathways (see Appendix for full data sets). Color codes indicate log2 fold up- or 
down-regulation (red and blue, respectively) of transcripts as in Fig. 7A. Identified immune regulatory 
pathways include cytokine-cytokine receptor interaction, the RIG-I-like receptor signaling pathway, and the 
Toll-like receptor signaling pathway with many down-regulated genes.

(B) Box plots illustrate log2 fold changes of selected genes, which are targets of miRNAs encoded by wt EBV 
and associated with adaptive immune responses or the p53 signaling pathway. Many but not all genes in 
these KEGG pathways are down-regulated in wt compared with ΔmirALL EBV-infected B cell. Genes 
previously reported to be targets of EBV miRNAs and common housekeeping genes are shown. The blue 
background shadings indicate top down-regulated genes in “wt vs. ΔmirALL” EBV-infected B cells five days 
post infection as defined in Fig. 7A.
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Key molecules in chemokine signaling and TGF-beta signaling such as TGFBR2 were 
included in the top down-regulated genes in B cells infected with +mirBART compared with 
wt EBV (Fig. 9B), but Fc receptor-encoding genes in particular were widely down-regulated 
at transcript levels (see Fig. 9B with “B cell receptor signaling pathway” and “Fc receptors”). 
Many products of these down-regulated Fc receptor-encoding genes including CD72, 
FCGR2B (FcγRIIB), FCRL2, FCRL4, and FCRL5 are inhibitory B cell receptor (BCR) co-
receptors (Tsubata, 2012), whereas FCRL1 is an activating co-receptor molecule (Leu et al., 
2005). Since FCGR2B is known to induce apoptosis upon crosslinking on naive B cells 
(Tzeng et al., 2005), +mirBART EBV-unique miRNAs may promote a better expansion and 
survival of EBV-infected B cells by repressing inhibitory BCR co-receptors in a given 
microenvironment in vivo. 
 
 
 
 
 
 
 
(A) KEGG enrichment analysis of selected pathways, which are listed according to their significances in 
descending order. The analysis on the basis of diﬀerentially regulated genes comparing "+mirBART vs. wt" 
EBV-infected B cells is shown. For two of six donor, transcripts are mapped and plotted together with the 
linked pathways as in Fig. 8A (see Appendix for full data sets). Generally, the extent of fold change are lower 
in "+mirBART vs. wt" than in "wt vs. ΔmirALL" EBV-infected B cells, which may be due to the low expression 
level of +mirBART EBV-unique miRNAs compared with miRNAs encoded by wt EBV (Fig. 4C). The p-values 
for these pathways are similar comparing diﬀerentially regulated genes in "+mirBART vs. wt" and "wt vs. 
ΔmirALL" EBV-infected B cells suggesting that both miRNAs of wt EBV and +mirBART EBV-unique miRNAs 
regulate the same pathways but to a diﬀerent degree.

(B) Box plots illustrate log2 fold changes of selected genes, which are targets of +mirBART EBV-unique 
miRNAs and associated with TGF-beta signaling, chemokine signaling, and B cell receptor signaling. The 
down-regulated genes include many Fc receptors (FCGR2B, FCRLA, FCRL1/2/4/5), which showed 
consistent down-regulation in +mirBART compared with wt EBV-infected B cells. Common housekeeping 
genes are shown as well. The blue and red background shadings indicate top down- or up-regulated genes 
comparing +mirBART versus wt EBV-infected B cells five days post infection as defined in Fig. 7A.
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3. Viral miRNA-induced reductions of transcripts correlate with lower protein 
levels in EBV-infected B cells 
I quantified the protein levels of genes whose transcript levels were reduced according 
to my transcriptome analyses (Result section 2; Fig. 8B, Fig. 9B). I performed ELISAs to 
quantify the concentrations of released cytokines in cell culture supernatants. I also 
employed western blot detection and flow cytometry to measure intracellular and cell 
surface protein levels, respectively (Fig. 10). 
IL12B (encoding IL-12p40) was the most strongly and consistently down-regulated gene 
comparing wt versus ΔmirALL EBV-infected B cells (“wt vs. ΔmirALL”; Fig. 8B). The extent 
of regulation speaks for a direct role of wt EBV miRNAs in regulating IL12B. Since IL12B is 
a subunit of two cytokines, IL-12 and IL-23 (Szabo al., 2003), I measured the concentration 
of IL12B in the supernatants of B cells infected either with wt EBV or with ΔmirALL EBV. As 
a result, the concentration of IL12B is lower in supernatants of wt compared with ΔmirALL 
EBV-infected B cells at four and eleven days post infection (Fig. 10A). 
The pro-apoptotic gene PMAIP1 was another gene that was consistently down-
regulated at the transcript level in wt versus ΔmirALL EBV-infected B cells (Fig. 10B). My 
colleague Manuel Albanese performed western blot analysis on whole cell lysates from B 
cells infected either with wt or with ΔmirALL EBV to detect PMAIP1. The protein level of 
PMAIP1 was reduced in wt EBV-infected B cells compared with ΔmirALL EBV-infected B 
cells (Fig. 10B), confirming the regulation at the transcript level (Fig. 8B). 
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Figure 10 EBV miRNAs regulate steady state protein levels in EBV-infected B cells 
I quantified the protein expression of genes that were down-regulated at transcript levels by wt EBV miRNAs 
or +mirBART EBV-unique miRNAs. For cytokines, intracellular proteins, and cell surface proteins, I employed 
ELISA, western blotting, and Flow cytometry analysis, respectively. With the exception of certain cell surface 
proteins, genes that were down-regulated in the transcriptome analysis showed reduced protein levels.

(A) IL12B (IL-12p40) concentrations in supernatants (between four to eight, or 11 to 15 days post infection) 
from B cells infected with wt or ΔmirALL EBV were measured with ELISA. IL12B secretion was reduced in wt 
compared with ΔmirALL EBV-infected cells early after infection. Three independent biological replicates are 
shown. IL12B concentrations were normalized to 1 x 106 cells. *: p<0.05, two-tailed ratio T test.

(B) Steady state protein levels were investigated by western blot detection using cell lysates from ΔmirALL 
and wt EBV-infected cells five days post infection. PMAIP1 was down-regulated in cells infected with wt 
compared with ΔmirALL EBV early after infection. The signal of PMAIP1 and β-Actin (an internal reference 
gene) are normalized to the signal of Tubulin.

(C)(D) Quantification of cell surface protein levels of genes diﬀerentially regulated by viral miRNAs. Primary B 
cells were infected with wt or ΔmirALL EBV, immunostained, and flow cytometry analysis was performed 
prior to infection and five days post infection using antibodies directed against the indicated gene products. 
*: p<0.05, **: p<0.01, ***: p<0.001 of two-tailed ratio T test. Means of three to five biological replicates are 
shown with SD. (C) wt EBV-infected cells showed down-regulated cell surface expression levels of many 
immune synapse-related proteins. Ratios of Median Fluorescence Intensity (MFI) of wt versus ΔmirALL 
infected cells are shown as percentage. Manuel Albanese performed the analysis. (D) +mirBART EBV-unique 
miRNAs down-regulate cell surface expression levels of Fc receptors and immune globulins. Ratios of MFI 
(+mirBART versus wt infected cells) are shown as percentage. I performed the analysis.
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Lastly, we performed immunostainings followed by flow cytometry analysis to quantify 
the amounts of several cell surface proteins encoded by genes identified to be top down-
regulated genes by EBV miRNAs (Fig. 8B, Fig. 9B). At five days post infection, the majority 
of these miRNA-targeted targets including CD40, CD80, ICOSLG, and ICAM1 showed 
reduced surface protein levels on wt compared with ΔmirALL EBV-infected B cells (Fig. 8B, 
Fig. 10B). Similarly, protein levels of FCGR2B and the immuno globulin light chain lambda, 
but not kappa, were reduced on the cell surface of +mirBART compared with wt EBV-
infected B cells (Fig. 9B, Fig. 10B).  
These findings indicate that reduced transcript levels corresponded to lower protein 
levels in general. The few exceptions speak for unknown mechanisms, which are regulated 
by EBV miRNAs and indirectly control the levels of functional proteins in EBV-infected B 
cells.  
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4. EBV miRNAs redundantly and robustly repress targeted mRNAs 
A high-throughput screening like my transcriptome analysis requires a subsequent 
independent validation to confirm the findings. Here I employed various methods to prove, 
re-evaluate, and refine direct targets of EBV miRNAs. The transcriptome analysis provided 
me with information about mRNA reduction by viral miRNAs, but mRNA levels can be 
regulated directly or indirectly. I performed AGO2 RIP-Seq not only to identify the 
catalogues of RISC-incorporated miRNAs (Result section 1) but also to find transcripts 
directly bound by EBV miRNAs. Combining this information with my transcriptome analysis, 
I performed an efficient screening of the direct targets of viral miRNAs. I also employed 
luciferase reporter assays for the final validation of transcripts directly repressed by EBV 
miRNAs. Here I mainly focused on miRNAs encoded by wt EBV. 
 
4.1 Analysis of AGO2 RIP-Seq using IPO7 as a positive control 
AGO2 RIP enriches not only miRNAs but also targeted mRNAs (Meister et al., 2004), 
which are trapped in the RISC to be degraded, eventually. To evaluate whether my RIP-Seq 
resulted in an enrichment of reads of mRNAs that EBV miRNAs target, I analysed the 3’-
UTR of IPO7 (Fig. 11 top panel), a well-established target of ebv-miR-BART3 (Dölken et al., 
2010). For the bioinformatical analysis of mapped reads, we defined an enrichment score, 
which embodies the enrichment of reads comparing wt with ΔmirALL EBV-infected B cells 
(see Materials & Methods for details). For all six donors tested, the miR-BART3 binding 
position in the 3’-UTR of the IPO7 mRNA provided a clear peak with a high enrichment 
score (Fig. 11 top panel) indicating that the AGO2 RIP-Seq was sensitive enough to capture 
the differential binding of EBV miRNAs to mRNA molecules. 
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Figure 11 EBV miRNAs bind target mRNAs 
AGO2 RIP-Seq analysis of B cells infected with wt EBV or ΔmirALL EBV. EBV-infected B cells were lysed 
and RIP-Seq against AGO2 was performed five days post infection. Resulting reads were mapped to the
Ad1 Ad2
Ad3 Ad4
Ad6Ad5
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4.2 Prediction of direct targets of EBV miRNAs 
To define the threshold levels that likely classify direct targets of EBV miRNAs, I 
analysed the 3’-UTRs of selected mRNAs of top down-regulated genes according to the 
transcriptome analysis (Result section 2) and predicted to be direct targets by TargetScan 6 
(an in silico algorithm to predict direct targets of miRNAs; Garcia et al., 2011). The 3’-UTR of 
IL12B is shown in Fig. 11 (bottom) as an example. IL12B was among the most strongly 
down-regulated gene product regarding transcript and protein levels by wt EBV miRNAs 
(Fig. 8B, Fig. 10A) and TargetScan predicted that IL12B could be directly controlled by ten 
EBV miRNAs. Still, only donors Ad1 and Ad4 showed a peak with a high enrichment score 
(Fig. 11). Similarly, the 3’-UTR of the viral miRNA-regulated PMAIP1 (Fig. 8B, Fig. 10B) 
showed high enrichment scores only in three infected B cells out of six donors 
(Supplementary Fig. 3).  
From these observations, I decided to select the top read-enriched 3’-UTRs to find 
transcripts directly bound by EBV miRNAs. We defined the criteria for this purpose as 
follows: a transcript with a stretch of >20 nucleotides with an enrichment score of >0.6 in its 
3’-UTR in two or more donors. In the comparison of “wt vs. ΔmirALL” EBV-infected B cells, 
2235 genes including IPO7, IL12B, PMAIP1, CCL22, CD40, and FAS, which were down-
regulated at the level of transcript levels (Fig. 8B), fulfilled these criteria (Supplementary 
Table 2 for the full list of identified genes). 
 
4.3 Luciferase reporter assays with the 3’-UTRs of IL12B and PMAIP1 
Among the candidates discussed in Result section 4.2, I selected IL12B and PMAIP1 to 
evaluate if they are direct targets of viral EBV miRNAs. I performed luciferase reporter 
assays with wild-type or mutated 3’-UTRs of IL12B and PMAIP1. In these assays, miR-
BHRF1-2, miR-BART1, or miR-BART2 inhibited the luciferase activity of the IL12B reporter 
(Fig. 12A left). I mutated the predicted binding sites of miR-BART1 or miR-BART2, which 
human genome (hg19 ‘core’ chromosome-set) and 3’-UTRs of selected genes were examined comparing wt and 
ΔmirALL EBV-infected B cells. The normalized read enrichment in wt EBV-infected B cells (orange line), +mirBART 
EBV-infected B cells (blue line), and enrichment scores (yellow line, see Materials & Methods) are shown for all six 
donors. The presented data were acquired from samples described in Fig. 4.

(Top) The 3’-UTR of IPO7 mRNA is a well-known target of ebv-miR-BART3 and the enrichment score is very high at 
the exact binding position of ebv-miR-BART3 in all six samples. This result indicates that the AGO2 RIP-Seq 
experiments captured the viral miRNA- targeted transcripts.

(Bottom) The 3-’UTR of IL12B mRNA is shown. IL12B is the strongly down-regulated gene in wt compared with 
ΔmirALL EBV-infected B cells, but in AGO2 RIP-Seq only two out of six samples had high enrichment scores.
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abrogated the ability of miR-BART1 or miR-BART2 to inhibit the IL12B reporter (Fig. 12A left, 
Supplementary Fig. 4) suggesting the direct binding and repression of IL12B by viral 
miRNAs. In addition, miR-BART10 and miR-BART22, which are present in +mirBART EBV 
but not in wt EBV, directly inhibited the luciferase activity of the IL12B 3’-UTR reporter (Fig. 
12A left, Supplementary Fig. 4). Mutations of their predicted target sites only partially 
relieved the inhibition by these miRNAs suggesting the presence of additional unknown 
binding sites for miR-BART1, -BART10, and –BART22 in the IL12B transcript.  
Similarly, the PMAIP1 reporter was directly bound and repressed by miR-BART2 (Fig. 
12B right, Supplementary Fig. 4). There are two binding sites for miR-BART2. Mutations of 
either of these sites abrogated the repressive function of miR-BART2 suggesting that miR-
BART2 needs both sites to suppress PMAIP1 expression fully (Fig. 12B right). 
Combining RNA-Seq, AGO2 RIP-Seq, in silico prediction, and 3’-UTR reporter assays, I 
identified a number of miRNAs encoded in wt EBV that directly control the expression of 
IL12B and PMAIP1. 
 
4.4 Luciferase reporter assays with 3’-UTRs of FCGR2B and TGFBR2 
I performed 3’-UTR reporter assays with the 3’-UTRs of FCGR2B and TGFBR2 that 
were among the top down-regulated genes repressed by +mirBART EBV-unique miRNAs 
(Fig. 12B). I tested the wild-type 3’-UTRs of these transcripts in combination with a number 
of EBV miRNAs. I selected viral miRNAs that have a 6-mer seed complementarity (Bartel, 
2009) as the minimal requirement to be considered. As a result, the FCGR2B reporter was 
inhibited by multiple +mirBART EBV-unique miRNAs (miR-BART7 and miR-BART19), but 
none of wt EBV miRNAs had an effect (miR-BHRF1-1 and miR-BART2; Fig. 12B). Similarly, 
different +mirBART EBV-unique miRNAs (miR-BART10 and miR-BART20), but not the wt 
EBV miRNA miR-BART2, significantly inhibited the luciferase activity of the TGFBR2 
reporter. These findings suggested that several +mirBART EBV-unique miRNAs, but not wt 
EBV miRNAs, directly repress FCGR2B and TGFBR2 in line with my transcriptome analysis 
(Result section 2.4; Fig. 7B, Fig. 9B). 
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Figure 12 EBV miRNAs redundantly bind and repress target mRNAs 
I confirmed IL12B and PMAIP1 as direct targets of EBV miRNAs using luciferase reporter assays. Several viral 
miRNAs target IL12B redundantly. In addition, I validated TGFBR2 and FCGR2B as targets only of +mirBART EBV-
unique miRNAs.

(A) Luciferase reporter assays with 3’-UTRs of IL12B or PMAIP1 and single EBV miRNAs. I performed reporter 
assays with IL12B or PMAIP1 3’-UTRs cloned in psiCHECK-2 vectors. These genes were chosen because both 
IL12B and PMAIP1 were down-regulated in wt compared with ΔmirALL EBV-infected cells (Fig. 8B, 10A, 10B), and 
AGO2 RIP-Seq showed read enrichment within their 3’-UTRs. The IL12B reporter was directly inhibited by five 
diﬀerent miRNAs, which include both wt miRNAs and +mirBART EBV-unique miRNAs suggesting a high 
redundancy of viral miRNAs regulating IL12B. The PMAIP1 reporter was similarly inhibited by one viral miRNA, 
miR-BART2. φ: empty vector, wt: wild-type 3’UTR, mut: 3’-UTR with mutations preventing the binding of EBV 
miRNAs. *: p<0.05, two-tailed unpaired T test for luciferase assay of wt 3’-UTR with empty vector. p-values are 
shown for the evaluation of mutations as indicated. Means of triplicates ± SD are shown.

(B) Luciferase reporter assays with 3’-UTRs of FCGR2B or TGFBR2. These genes were repressed in +mirBART 
compared with wt EBV-infected cells both at transcript and at protein levels (Fig. 9B, 10D). Several +mirBART EBV-
unique miRNAs but no wt EBV miRNAs inhibited the 3’-UTR reporters of these genes. *: significant in two-tailed 
unpaired multiple T test using the Sidak-Bonferroni method of luciferase assay with empty vector. Mean of 
triplicates ± SD are shown.
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5. wt EBV-infected B cells release less pro-inflammatory cytokines than 
ΔmirALL EBV-infected cell 
The KEGG pathway enrichment analysis in the Result section 2.3 showed that cytokines 
appeared to be among the canonical targets of EBV miRNAs, particularly in wt EBV-
infected B cells (Fig. 8). To examine the effects of EBV miRNAs on cytokine secretion from 
EBV-infected B cells, I closely investigated the regulation of several genes included in the 
category “Cytokine-Cytokine receptor interaction”. I analysed the levels of transcripts and 
cytokine concentrations with RNA-Seq and ELISA, respectively. 
 
5.1 Transcriptomic profiles of cytokines 
Transcript levels of genes encoding pro-inflammatory cytokines like IL-6 (IL6, TNF-α, IL-
8, and IL-15), but not the anti-inflammatory cytokine IL-10, in wt EBV-infected B cells were 
lower compared with ΔmirALL EBV-infected B cells (Fig. 8B, Supplementary Table 1). In 
addition, cytokines like IL-12 and IL-23, which induce helper T cell (Th) differentiation, were 
down-regulated in wt compared with ΔmirALL EBV-infected B cells (Fig. 8B). IL-12 and IL-
23 are heterodimers that consist of a common subunit IL12B (IL-12p40), which pairs with 
IL12A (p35) or IL23A (p19), respectively (Szabo al., 2003). Interestingly, IL12A was 
unaffected but both IL12B and IL23A were down-regulated by wt EBV miRNAs (Fig. 8B). 
Therefore, the reduced amount of the IL-23 heterodimer (p19/p40) secreted from EBV-
infected B cells was expected, but the situation for IL-12 heterodimer (p35/p40) was not 
obvious. 
Taken together, according to the transcriptomic analysis of EBV-infected B cells, 
miRNAs encoded in wt EBV appeared to interfere with important antiviral immune 
responses preventing infected cells from producing high levels of pro-inflammatory 
cytokines and cytokines that promote Th cell differentiation. 
 
5.2 Cytokine profiling by ELISA 
I measured the secretion of pro-inflammatory and Th differentiation cytokines as well as 
an anti-inflammatory cytokine described in Result section 5.1 and asked whether EBV 
miRNAs control not only mRNA levels but also cytokine secretion. I prepared primary B 
cells from three different donors and infected them either with wt EBV or with ΔmirALL EBV. 
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After four or eleven days, I seeded the identical number of cells for each condition in fresh 
medium, cultivated the cells for four additional days, and quantified the concentration of 
cytokines in the supernatants with ELISA (Fig. 13). For the detection of the pro-
inflammatory cytokines IL-6 and TNF-α, I added CpG DNA, which stimulates TLR9 and 
enhances the secretion of these cytokines from EBV-infected cells (Iskra et al., 2010). This 
step was necessary to reliably detect IL-6 and TNF-α. The wt EBV-infected B cells secreted 
consistently less IL-6 and TNF-α than B cells infected with ΔmirALL EBV. Secretion of IL-12 
(p35/p40) and IL-23 (p19/p40), both of which contain the IL12B subunit, were also 
significantly reduced in wt compared with ΔmirALL EBV-infected cells (Fig. 13 right), even 
though IL12A, which encodes p35, was not down-regulated at the transcript level (Fig. 8B). 
This finding suggests that IL-12p40, the product of IL12B that is strongly controlled by viral 
miRNAs (Fig. 6B, Fig. 7A, Fig. 8B), was the limiting factor in IL-12 and IL-23 secretion. In 
contrast to these cytokines, the secretion of the anti-inflammatory cytokine IL-10 showed 
no clear regulation by viral miRNAs regardless of the addition of CpG DNA (Fig. 13). This 
result is consistent with my transcriptome analysis (Fig. 8B). 
Collectively, ΔmirALL EBV-infected B cells secrete higher amount of several pro-
inflammatory cytokines than wt EBV-infected B cells. EBV miRNAs control not only the 
transcript levels (Result section 5.1) but also the secretion of cellular pro-inflammatory 
cytokines that may enhance immune responses of the host against EBV-infected B cells. 
Even further, EBV miRNAs reduce IL-12 and IL-23 secretion, which may result in the 
suppression of helper T cell differentiation. IL-12 induces the differentiation of naive CD4+ T 
cells to type 1 helper T cells (Th1 cells), which are known to act against virus-infected cells. 
It is thus conceivable that EBV benefits from a reduced number of Th1 cells that virus 
controls via its many viral miRNAs. 
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Figure 13 wt EBV-infected B cells secrete less pro-inflammatory cytokines compared with ΔmirALL 
EBV-infected cells 
IL-12, IL-23, IL-6, TNFα, and IL-10 concentrations in supernatants (harvested between 4 to 8, or 11 to 15 
days post infection) from B cells infected with wt or ΔmirALL EBV were measured with ELISA. Secretions of 
the Th diﬀerentiation cytokines IL-12 and IL-23, and the pro-inflammatory cytokines IL-6 and TNFα were 
reduced from wt compared with ΔmirALL EBV-infected cells. In contrast, the secretion of an anti-
inflammatory cytokine, IL-10, appeared to be not regulated by viral miRNAs. Three independent biological 
replicates are shown. The cytokine concentrations were normalized to 1x106 cells. *: p<0.05. p-values of 
two-tailed ratio T test are shown. (Left column) Concentrations of IL-12, IL-23, and IL-10. (Right column) 
Concentrations of IL-6, TNFα, and IL-10. CpG DNA was added at two time points (4 and 11 days post 
infection) to induce the secretion of pro-inflammatory cytokines from EBV-infected B cells.
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6. Reduced IL-12 secretion from wt EBV-infected B cells interferes with Th1 
differentiation of naive CD4+ T cells 
The cytokine IL-12 induces the differentiation of naive CD4+ T cells to type 1 helper T 
cells (Szabo al., 2003), and both its transcript level and secretion are reduced by wt EBV 
miRNAs (Result section 5). Based on this observation, I hypothesized that the reduced 
secretion of IL-12 from wt compared with ΔmirALL EBV-infected B cells suppresses Th1 
differentiation. To investigate this hypothesis, I employed co-culture experiments. 
 
6.1 Th1 differentiation assay with co-cultured naive CD4+ T cells and infected B cells 
I performed co-culture experiments with naive CD4+ T cells and autologous B cells 
infected with wt or ΔmirALL EBV (Fig. 14) to prove my hypothesis. I proposed that EBV 
miRNAs repress the secretion of IL-12 from EBV-infected B cells and thereby suppress the 
differentiation of helper T cells. I sorted naive CD4+ T cells from human donors and stored 
at -80℃. In parallel, I sorted primary B cells from the same donors, infected them either 
with wt or with ΔmirALL EBV, and cultivated the two infected cell populations for five days. 
Naive CD4+ T cells were then thawed, pulsed with CellTrace Violet (to identify stimulated, 
proliferating cells later), and mixed with EBV-infected B cell in the presence of anti-
CD3/anti-CD28 antibodies (to activate T cells and induce their differentiation) for seven 
days (Fig. 14A). Prior to the analysis, T cells were re-stimulated with PMA/Ionomycin for five 
hours to induce the secretion of IFN-γ, which is a marker for differentiated Th1 cells. As a 
result, wt EBV-infected B cells reduced the size of the Th1 population compared with 
ΔmirALL EBV-infected cells (Fig. 14B, C). T cells cultivated either with ΔmirALL EBV or with 
wt EBV proliferated equally (Fig. 14B left panel) indicating that EBV miRNAs interfered with 
Th1 differentiation but did not prevented the proliferation of T cells.  
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Figure 14 Low IL-12 secretion from wt EBV-infected B cells interferes with Th1 diﬀerentiation of naive 
CD4+ T cells 
Th1 populations were quantified after co-culture experiments of naive CD4+ T cells and infected B cells in 
an in vitro differentiation assay. IL-12 is a key cytokine inducing Th1 differentiation of naive CD4+ T cells 
(Teng et al., 2015). The reduced secretion of IL-12 from wt EBV-infected B cells (Fig. 13) resulted in the 
reduction of the Th1 population compared with ΔmirALL EBV-infected B cells. T cells cultivated with wt 
or ΔmirALL EBV-infected B cells proliferated equally under αCD3/αCD28 stimulation.
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6.2 Neutralization of IL-12 prevents Th1 differentiation 
I performed similar co-culture experiment but used an anti IL12B (IL-12p40) antibody to 
neutralize the IL-12 cytokine released by wt or ΔmirALL EBV-infected B cells and measured 
the contribution of IL-12 to Th1 differentiation (Fig. 14D). As an appropriate control, I used 
an antibody of the same isotype as the IL-12p40 neutralizing antibody. The anti-IL12B 
antibody, compared with an irrelevant isotype antibody, suppressed Th1 differentiation of T 
cells co-cultured with ΔmirALL EBV-infected B cells abrogating the difference between wt 
and ΔmirALL EBV-infected B cells regarding the size of Th1 population (Fig. 14D). This 
finding indicates that EBV miRNAs interfere with the differentiation of Th1 cells by reducing 
the secretion of IL-12 from EBV-infected B cells.  
 
 
 
 
 
(A) Schematic presentation of the Th1 diﬀerentiation assay. The naive CD4+ T cells were pulsed with Cell 
Trace Violet to identify proliferating cells and cultivated for 7 days with autologous B cells that had been 
infected with EBV five days earlier. αCD3/αCD28 antibodies were added to activate naive CD4+ T cells and 
to induce their diﬀerentiation. T cells were re-stimulated for 5 hours with phorbol 12-myristate 13-acetate 
(PMA) and ionomycin to induce IFN-γ production prior to immunostaining. Th1 populations of proliferating T 
cells were quantitated with intracellular IFN-γ staining and flow cytometery analysis.

(B) Th1 populations appeared after the co-culture of naive CD4+ T cells with B cells infected with wt or 
ΔmirALL EBV. wt EBV-infected B cells reduced the size of the Th1 population compared with ΔmirALL EBV-
infected B cells. (Left) A representative flow cytometry analysis of the CellTrace Violet staining of CD4+ T 
cells after the co-culture with B cells infected with wt or ΔmirALL EBV. T cells cultivated with wt or ΔmirALL 
EBV-infected B cells proliferated equally under αCD3/αCD28 stimulation. (Right) A representative flow 
cytometry analysis of intracellular IFN-γ staining after co-cultures of naive CD4+ T cells with B cells infected 
either with wt or with ΔmirALL EBV. The IFN-γ positive Th1 populations are shown as percentage of 
proliferating CD4+ T cells.

(C) Statistical analysis of the percentage of IFN-γ positive, proliferating T cells after the co-culture 
experiment of naive CD4+ T cells with B cells infected either with wt or with ΔmirALL EBV at two diﬀerent cell 
ratios as indicated. *: p<0.05. p-values of two-tailed ratio T test are shown.

(D) The eﬀect of IL12B neutralization on the fraction of IFN-γ positive T cells in co-cultures with wt or 
ΔmirALL EBV-infected B cells. B cell:T cell ratio was 1:1. Cytokine neutralization was achieved with 5 μg/ml 
anti-IL12B (IL-12p40, a subunity of IL-12) antibodies and controls were obtained with an irrelevant antibody 
of the same isotype. IL12B neutralization abrogated most of the stimulatory eﬀect of ΔmirALL-infected cells 
on Th1 diﬀerentiation. *: p<0.05, **: p<0.01.
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7. EBV miRNAs reduce antigen presentation and suppress recognition of 
infected B cells by CD4+ T cells 
The transcriptome analysis described in Result section 2 revealed that EBV miRNAs 
regulate genes included in the KEGG pathway “Cell adhesion molecules” that 
encompasses immunological synapse-related genes. These EBV miRNAs-regulated genes 
include co-stimulatory molecules, cell adhesion molecules, and MHCs. Down-regulation of 
these genes will lead to reduced antigen presentation by EBV-infected B cells, hence less 
recognition by T cells. To evaluate this possibility, Manuel Albanese quantitated protein 
levels of these gene products on the surface of infected B cells, and determined the 
activities of effector CD4+ T cells against EBV-infected B cells. 
 
7.1 Reduction of MHC molecules, co-stimulatory molecules, and cell adhesion 
molecules on the surface of infected B cell by EBV miRNAs 
For the quantification of antigen presentation, we performed immunostainings of MHC 
molecules followed by flow cytometry with B cells infected either with wt EBV or with 
ΔmirALL EBV. At five and 15 days post infection, protein levels of all three major MHC class 
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Figure 15 EBV miRNAs reduce antigen presentation by infected B cells 
Antigen presentation to eﬀector T cells via MHC class I and II by EBV-infected B cells were assessed by flow 
cytometry analysis. Ratios of MFI (wt versus ΔmirALL infected cells) of individual HLA molecules prior to 
infection, five days post infection, or 15 days post infection are shown. wt EBV-infected B cells showed 
lower protein levels of major MHC class molecules on the cell surface compared with ΔmirALL EBV-infected 
cells, suggesting a reduced antigen presentation early after infection. *: p<0.05, **: p<0.01. Means of three to 
five biological replicates are shown with SD.
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II molecules were significantly lower in wt EBV-infected B cells compared with ΔmirALL 
EBV-infected B cells (Fig. 15) suggesting a reduced antigen presentation to CD4+ T cells. 
The protein levels of MHC class I molecules were mildly but significantly lower at both time 
points, too (Fig. 15). These results suggested that, as early as five days post infection, EBV 
miRNAs in infected B cells may inhibit antigen epitope presentation by both MHC class I 
and II molecules. 
In addition, several, but not all co-stimulatory molecules (CD40, CD80, and ICOSLG) 
and one cell adhesion molecule (ICAM1) were reduced at cell surface protein levels in wt 
EBV-infected B cells compared with ΔmirALL EBV-infected B cells (Fig. 10C). Together, 
these findings support a hypothesis that EBV miRNAs inhibit immune responses of T cells 
by reducing antigen presentation of EBV-infected B cells. The viral miRNAs control genes 
including MHC molecules, co-stimulatory molecules, and adhesion molecules necessary for 
immunological synapse formation. 
 
7.2 Reduced IFN-γ secretion from effector CD4+ T cells upon co-culture with wt EBV-
infected B cells 
To test the hypothesis stated in Result section 7.1, Albanese expanded CD4+ T cells ex 
vivo by repeated stimulation with an irradiated autologous wt EBV-infected Lymphoblastoid 
Cell Line (LCL). The expanded EBV-stimulated T cells were incubated with primary B cells, 
which were infected either with wt EBV or with ΔmirALL EBV and cultivated for five days. 
For the evaluation of T cell activities, the concentration of secreted IFN-γ was measured of 
these co-culture experiments after 16 hours (Fig. 16A). 
The activity of the LCL-stimulated, EBV antigen-specific CD4+ T cells from different 
donors were analysed under autologous or HLA-matched conditions. Release of IFN-γ by 
EBV-stimulated CD4+ T cells was consistently reduced when co-cultured with wt versus 
ΔmirALL EBV-infected B cells as targets, both in autologous and HLA-matched situations 
(Fig. 16B). Importantly, CD4+ T cells were not activated by mismatched infected B cells in 
this assay, indicating that the observed activation of CD4+ T cells was EBV-specific and 
HLA class II-restricted (Fig. 16B). 
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Figure 16 EBV miRNAs interfere with recognition and killing of infected B cells by CD4+ T cells 
Recognition of EBV-infected B cells by EBV antigen-specific CD4+ T cells were assessed in co-culture 
experiments. In line with the reduced antigen presentation (Fig. 15), EBV antigen-specific CD4+ T cell 
secreted less IFN-γ and showed reduced cytotoxicity of EBV-infected B cells. It thus appeared that miRNAs 
encoded by wt EBV protect infected B cells from recognition by CD4+ T cells.
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7.3 Protection of wt EBV-infected B cells from cytolytic effector CD4+ T cells 
EBV antigen-specific CD4+ T cells have cytolytic activity (Adhikary et al., 2006). Thus, 
Albanese also tested this function in our co-culture assays. In allogeneic HLA-matched 
conditions, EBV antigen-specific CD4+ T cells consistently showed stronger cytolysis of 
target B cells infected with ΔmirALL EBV than with wt EBV (Fig. 16C).  
Taken together, EBV miRNAs negatively affected the recognition of infected B cells by 
HLA class II-restricted CD4+ T cells, which showed an impaired cytokine secretion and 
reduced killing of the infected B cells early after infection. 
  
(A) Schematic presentation of the co-culture experiment with EBV-stimulated T cells and B cells infected 
with wt or ΔmirALL EBV. CD4+ T cell were isolated from PBMCs or adenoid biopsies, sorted, and stimulated 
with irradiated autologous EBV-infected B cells biweekly to expand CD4+ EBV-specific eﬀector T cells. 
Expanded CD4+ T cells were cultivated with autologous, HLA-matched allogeneic, or mismatched B cells 
infected either with wt or with ΔmirALL EBV strains at day five post infection. IFN-γ secretion or cytotoxic 
eﬀects on infected B cells were analyzed 16 hours later.

(B) Activation of EBV antigen-specific CD4+ T cells with autologous, HLA-matched allogeneic, or 
mismatched B cells infected either with wt or with ΔmirALL EBV. The eﬀector: target ratio was 1:1, the 
readout was IFN-γ secretion levels quantitated with ELISA. Both autologous and allogeneic CD4+ T cells 
cultivated with wt EBV-infected cells secreted less IFN-γ compared with T cells cultivated with ΔmirALL 
EBV-infected cells, indicating that wt EBV-infected B cells are better protected from the recognition by 
eﬀector CD4+ T cells than ΔmirALL EBV-infected B cells. The HLA types of Donor 32 are as follows: HLA-
DRB1*1501, HLA-DRB1*0701, HLA-DQB1*0602, HLA-DQB1*0303, HLA-DPB1*0401. Matched HLA types 
are shown. n.a: not applicable.

(C) Cytotoxic activities of EBV antigen-specific CD4+ T cells. The cytotoxic capacity of CD4+ T cells was 
analyzed with calcein release assays after co-culture with HLA-matched allogeneic B cells infected with wt 
or ΔmirALL EBV. The experiments were performed at various eﬀector:target ratios as indicated. CD4+ T cells 
killed more ΔmirALL EBV-infected B cells than wt EBV-infected B cells. wt EBV miRNAs thus protect EBV-
infected B cells from cytotoxic EBV antigen-specific CD4+ T cells. p-values of two-tailed ratio T test are 
shown.
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Discussion 
Primary B cells newly infected with EBV are a successful model to reveal the 
phenotypes and molecular mechanisms controlled by viral miRNAs 
EBV miRNAs regulate apoptosis and the cell cycle five days post infection 
EBV miRNAs have anti-apoptotic and pro-proliferative cellular functions early after 
infection (Feederle et al., 2011a; 2011b; Seto et al., 2010). In my transcriptome and KEGG 
enrichment analyses I confirmed that genes associated with apoptosis, the cell cycle, and 
p53 signaling were regulated by both wt EBV miRNAs and +mirBART EBV-unique miRNAs 
(Fig. 8, Fig. 9). These results are in line with previous observations of my group. Viral 
miRNAs promote the proliferation of newly infected B cells comparing B cells infected with 
wt and ΔmirALL EBV (Seto et al., 2010), or +mirBART and wt EBV (Vereide et al., 2013). The 
identified pathways included several pro-apoptotic genes such as PMAIP1 (NOXA), BAX, 
and BBC3 (PUMA). PUMA was published recently to be regulated by a viral miRNA, miR-
BART5 (Choy et al., 2008). I also identified that PMAIP1 as a novel direct target of ebv-miR-
BART2. 
The most important miRNAs with pro-proliferative functions are miRNAs of the BHRF1 
cluster (Seto et al., 2010), but genes targeted by these miRNAs and responsible for the 
observed phenotypes are unknown (Grundhoff and Sullivan, 2011). In my experiment, I also 
did not identify genes that are directly regulated by BHRF1 miRNAs and contribute to anti-
apoptotic or cell cycle progressive functions, but such genes may be contained within the 
top class of genes classified to be consistently down-regulated by viral miRNAs (Result 
section 2.2; Fig. 7). Taken together, my infection model with primary B cells in combination 
with transcriptome analysis has the potential to study the molecular mechanisms that 
underlie the cellular phenotypes. 
 
The overlap between published targets of EBV miRNAs and down-regulated genes in 
my transcriptome analysis is limited 
The de facto standard to depict the repressive abilities of EBV miRNAs is IPO7 (Dölken 
et al., 2010; Klinke et al., 2014; Kuzembayeva et al., 2012; Skalsky et al., 2012; Vereide et 
al., 2013). Both my transcriptome analysis and AGO2 RIP-Seq are consistent with the 
previous findings that IPO7 is a direct target of a single viral miRNA, miR-BART3, encoded 
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by both wt and +mirBART EBV (Fig. 2, Fig. 8B, Fig. 11). In my experiments, IPO7 was 
among the top down-regulated genes comparing “wt vs. ΔmirALL”, and “+mirBART vs. 
ΔmirALL” EBV-infected B cells (Fig. 7B, Fig. 8B) supporting the view that the 136 genes in 
the intersection of the two data sets are canonical targets of miRNAs encoded by wt EBV 
(Result section 2.2; Fig. 7B). 
Published target genes like IPO7 (Dölken et al., 2010), LY75 (Skalsky et al., 2012), or 
BBC3 (Choy et al., 2008) were down-regulated by EBV miRNAs (Fig. 8B) in my model, but 
not every reported target behaved as expected in my experiments with B cells infected with 
different EBV strains. According to my transcriptome analysis, only a limited number of 
known targets were down-regulated. Reported EBV miRNA-targeted transcripts such as 
MICB (Nachmani et al., 2009), DICER1 (Iizasa et al., 2010), TOMM22 (Dölken et al., 2010), 
CASP3 (Vereide et al., 2013), DAZAP2 (Skalsky et al., 2012), or NLRP3 (Haneklaus et al., 
2012) showed no differences at transcript levels comparing wt versus ΔmirALL EBV-
infected B cells (Fig. 8B, Supplementary Table 1). Among them, TOMM22, (Dölken et al., 
2010) and DAZAP2 (Skalsky et al., 2012) were even reported along with IPO7 (ibid.) and 
LY75 (ibid.), respectively, both of which were included in the top class of down-regulated 
genes mediated by viral miRNAs in my experiments (Fig. 6B). These discrepancies between 
my transcriptome analysis and previously reported targets may be due to two reasons. 
First, the reported targets have been identified in established cell lines that differ from 
the primary infection model with newly infected primary B cells I employed. Cell lines in 
previous reports were of various origins and have been cultivated long-term in different 
conditions. These cell lines thus may have accumulated profound changes in their gene 
expression profiles. Using newly infected human primary B cells, a model that is close to 
primary infection in vivo, I could identify physiologically and virologically important targets 
of EBV miRNAs. 
Second, translational repression induced by miRNAs occurs prior to the degradation of 
transcripts (Djuranovic et al., 2012). Because of this, not all miRNA-regulated genes can be 
detected by RNA-Seq (Guo et al., 2010). An alternative approach to identify miRNA-
regulated genes is Ribosome-profiling. In most cases, differences in the level of transcripts 
obtained by Ribosome-profiling and RNA-Seq correlate, but Ribosome-profiling better 
reflects the effect of viral miRNAs on translational regulation as Ribosome-profiling record 
only actively translated mRNAs (Guo et al., 2010). 
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Immune regulatory pathways constitute canonical targets of viral miRNAs 
 
In my transcriptome and KEGG enrichment analyses I found that not only pro-
proliferative functions but also many immune regulatory pathways were regulated by viral 
miRNAs (Fig. 8A). This finding was particularly surprising because affected immune 
regulatory pathways ranged from innate immunity (TLR signaling, RIG-I-like receptor 
signaling, and Natural Killer cell mediated pathways) to adaptive immunity (antigen 
presentation, cytokine signaling, and cell adhesion molecules, which also encompass 
antigen presentation) suggesting that EBV miRNAs globally control immune responses in 
newly infected primary human B cells (Fig. 8A).  
In fact, I observed that viral miRNAs reduced the secretion of IL-12 and IL-23, which 
promote helper T cell differentiation. Specifically the reduced IL-12 secretion abrogated the 
differentiation of naive CD4+ T cells to type 1 helper T (Th1) cells, which have antiviral 
functions (Fig. 13, Fig. 14). Secretion of IL-6 and TNF- was also controlled by EBV 
miRNAs but required TLR9 stimulation with CpG DNA for reliable detection (Fig. 13). These 
results suggest an important role of EBV miRNAs in mitigating the pro-inflammatory 
microenvironment that EBV infection may cause.  
Moreover, we observed weaker antigen presentation by MHC class II molecules (Fig. 
15) and reduced recognition of B cells infected with wt EBV compared with ΔmirALL EBV 
by effector CD4+ T cells (Fig. 16). Similar to MHC class II molecules, MHC class I molecules 
were reduced in the early days of infection (Fig. 15) suggesting that EBV miRNAs inhibit 
antigen presentation of EBV-infected B cells to CD8+ as well as to CD4+ T cells.  
Evasion from EBV antigen-specific CD4+ T cell responses is thought to be particularly 
important early after infection. These CD4+ T cells predominantly target viral structural 
antigens that are directly derived from virus particles and presented by MHC class II of 
EBV-infected cells immediately after infection (Adhikary et al., 2007). On the other hand, 
EBV antigen-specific CD8+ T cells play their most important roles during the latent phase, 
because they mainly recognize epitopes from latent genes, complementing CD4+ T cell 
activities directed against EBV during the other phases of EBV’s life cycle (Mautner and 
Bornkamm, 2012). Our results indicated that all three signals, which are required for 
efficient recognition by effector T cells, i.e. antigen presentation (the first signal), co-
stimulatory molecules (the second signal), and pro-inflammatory cytokines (the third signal) 
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are simultaneously down-regulated during the pre-latent phase (Kalla and Hammerschmidt, 
2012) and in the early days of latent infection (Fig. 13, Fig. 14, Fig. 15, Fig. 16).  
Everything considered, these findings indicate that EBV miRNAs govern many T cell 
immune responses covering all aspects from differentiation to antigen presentation and 
recognition throughout the entire EBV infection process. 
 
 
Viral miRNAs encoded only by +mirBART EBV may regulate Fc receptors 
 
In addition to cell proliferation and immune regulation, which are prominently highlighted 
in the KEGG enrichment analysis comparing “wt vs. ΔmirALL” EBV-infected B cells (Fig. 7B), 
Fc receptors may be among the specific targets of +mirBART EBV-unique miRNAs (Fig. 9). 
Many genes encoding Fc receptors that are classified as inhibitory BCR co-receptors such 
as FCGR2B, FCRL2, FCRL4, FCRL5, and CD72 (Tsubata, 2012) were down-regulated at 
transcript levels in +mirBART compared with wt EBV-infected B cells (Fig. 9B). The only 
exception is the FCRL1 gene, which is known to encode an activating BCR co-receptor 
(Leu et al., 2005). The transcripts of these genes were not down-regulated in wt compared 
with ΔmirALL EBV-infected B cells (Fig. 7B) suggesting that these genes are exclusively 
controlled by +mirBART EBV-unique miRNAs.  
The natural ligands of most FCRLs are unknown, but the Fc portion of the IgG molecule 
is the ligand of FCGR2B (FcγRIIB; Tsubata, 2012). The receptor FCGR2B is activated by the 
antigen-Ig complex, which results in the apoptosis of mature naive B cells and plasma cells 
in vitro (Tzeng et al., 2005; Xiang et al., 2007). FCGR2B was expressed on the surface of 
EBV-infected B cells and was down-regulated by +mirBART EBV-unique miRNAs at day 
five post infection (Fig. 8B, Fig. 10D), which may prevent FCGR2B-induced apoptosis. The 
signaling pathways of other FCRLs, for which no ligands are known, are thought to inhibit 
BCR signaling (Tsubata, 2012). Therefore, it is possible that by controlling FCGR2B and 
FCRLs, +mirBART EBV-unique miRNAs protect EBV-infected B cells from apoptosis 
mediated by the activation of Fc receptors, which can be induced by various antibody-
antigen complexes in vivo. 
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Indirect gene regulation by EBV miRNAs 
EBV miRNAs have the potential to indirectly regulate a wide range of genes 
In my transcriptome analysis, I found, along with consistently down-regulated genes, 
similar numbers of genes up-regulated by viral miRNAs (Fig. 7A). Since the main function of 
miRNAs is to down-regulate gene expression (Bartel, 2004), this result is counter-intuitive. It 
may be because viral miRNAs down-regulate genes like transcriptional repressors thereby 
indirectly up-regulate many genes without directly binding and regulating them. 
Such indirectly regulated genes can be also seen in my comparative transcriptome 
analysis (Fig. 7B). Genes included in the intersections of the pair-wise comparisons of the 
data sets “wt vs. ΔmirALL”, “+mirBART vs. wt”, and “+mirBART vs. ΔmirALL” EBV-infected 
B cells are likely to be directly regulated targets of EBV miRNAs (Result section 2; Fig. 7B). 
However, the number of genes contained in the intersections is relatively small compared 
with all genes that were identified to belong to the top class of genese consistently down-
regulated by viral miRNAs. For example, only 136 out of 748 genes in the “wt vs. ΔmirALL” 
comparison are included in the “+mirBART vs. ΔmirALL” comparison (Fig. 7B). Compared 
with ΔmirALL EBV-infected B cells, the remaining 612 genes appear to be down-regulated 
in wt but not in +mirBART EBV-infected B cells. Again, this result is counter-intuitive 
because +mirBART EBV includes all 13 miRNAs encoded by wt EBV, and thus the 
transcripts down-regulated by wt EBV should also be down-regulated in +mirBART EBV-
infected B cells. A possible explanation for this observation is that +mirBART EBV-unique 
miRNAs indirectly up-regulate the 612 genes neutralizing or even reversing the repressive 
effects of the wt EBV miRNAs (see Fig. 17 with MIR155HG gene as an example). 
 
Viral miRNAs regulate certain cell surface molecules beyond translational control 
Inconsistencies between transcript and protein levels are an additional sign of indirect 
regulation by viral miRNAs. Genes like CD86 and CD274 were down-regulated at transcript 
levels in wt compared with ΔmirALL EBV-infected B, but the protein levels of both surface 
molecules did not correlated (Fig. 8B, Fig. 10C). These results may stem from the fact that 
viral miRNAs selectively hamper certain proteolytic pathways in EBV-infected cells leading 
to unaltered, or even elevated steady state levels of certain cellular proteins, independent of 
their reduced steady state transcript levels. 
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The indirect regulation of LMP1 by EBV miRNAs may be partly responsible for the 
unexpected regulation of cellular transcripts 
The viral gene BNLF1 (LMP1) is down-regulated in “wt vs. ΔmirALL” EBV-infected B 
cells, but is up-regulated in “+mirBART vs. wt” EBV-infected B cells (Fig. 17). LMP1 is 
known to up-regulate the expression of MIR155HG (BIC), which results in the up-regulation 
of miR-155, a miRNA hosted by the BIC transcript (Lu et al., 2008). In line with this report, 
LMP1, BIC, and miR-155 appeared to be regulated by viral miRNAs in my transcriptome 
analysis (Fig. 5B, Fig. 17). LMP1 is reported to be directly controlled by multiple BART 
cluster miRNAs (miR-BART1, -BART16, and -BART17; Lo et al., 2007). Therefore, it is 
possible that EBV miRNAs directly down-regulate LMP1, which then leads to reduced BIC 
transcript levels and lower concentration of miR-155 in wt vs. ΔmirALL EBV-infected B cells 
(Fig. 5B, Fig. 17). As miR-155 is reported to negatively regulate a number of downstream 
genes (Elton et al., 2013), it is conceivable that the down-regulation of miR-155 by viral 
miRNAs results in the up-regulation of direct targets of miR-155. In fact, I found six out of 
131 genes, which have been reported to be directly down-regulated by miR-155 (TarBase 
v7.0; Vlachos et al., 2015) and are counter-regulated with regard to BIC, LMP1, and miR-
155 (Fig. 17).  
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Figure 17 EBV miRNAs may indirectly regulate direct targets of miR-155 via LMP1 
Box plots illustrating log2 fold changes of selected genes. LMP1 and BIC (host gene of miR-155) transcript 
levels are strongly regulated by wt EBV miRNAs and +mirBART EBV-unique miRNAs. Six genes, which are 
previously reported to be targets of miR-155, are counter-regulated with respect to LMP1 or BIC. EBV 
miRNAs may control LMP1 which repress BIC and miR-155 expression hence leads to increased transcript 
levels of direct targets of miR-155.
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To make matters even more complicated, my transcriptome analysis suggested that the 
control of LMP1 by viral miRNAs is also partly indirect. This is because +mirBART EBV-
infected B cells have higher LMP1 transcript level than wt EBV-infected B cells (Fig. 17) 
despite the fact that miR-BART16 and 17, which reportedly directly control LMP1, are 
encoded only by +mirBART EBV but not by wt EBV.  
Taken together, EBV miRNAs control the expression of many cellular and certain viral 
genes directly and/or indirectly. As a result, they act not only as repressors but also as 
activators depending on the cellular context and regulatory factors, which control 
expression of other genes.  
  
 
The identification of direct targets of viral miRNAs by AGO2 RIP-Seq 
Enrichment scores revealed the direct binding of viral miRNAs to the 3’-UTR of IPO7 
To identify transcripts directly bound by viral miRNAs, I compared the enrichment of 
AGO2 RIP-Seq reads in wt versus ΔmirALL EBV-infected B cells. For a quantitative 
evaluation, we introduced an enrichment score, which took into account the amount of 
RISC-trapped reads in wt compared with ΔmirALL EBV-infected cells at the level of the 
individual donors of B cells. IPO7 is the most widely accepted target of viral miRNAs 
identified in the majority of high-throughput screens looking for direct targets of EBV 
miRNAs (Erhard et al., 2013; Klinke et al., 2014; Kuzembayeva et al., 2012; Riley et al., 
2012; Skalsky et al., 2012; Vereide et al., 2013). In line with the publications, the transcript 
level of IPO7 was also consistently down-regulated by wt EBV miRNA in my transcriptome 
analysis of all six donors (Fig. 8B). Since my AGO2 RIP-Seq data also had a high 
enrichment score at the exact binding site of miR-BART3, a reported EBV miRNA to control 
IPO7 (Fig. 11), I concluded that, based on enrichment scores, my AGO2 RIP-Seq can 
principally capture mRNAs directly bound by viral miRNAs.  
 
Viral miRNAs-regulated transcripts except IPO7 are poorly enriched in wt EBV-
infected B cells 
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Whereas enrichment scores of my AGO2 RIP-Seq data confirmed IPO7 as a bona fide 
target (Fig. 11), top consistently down-regulated genes like IL12B or PMAIP1 showed 
relatively poor enrichment scores on their transcripts (Result section 4.2; Fig. 11 bottom). 
The discrepancies between low RIP-Seq enrichment and high repression levels can be due 
to a differential degradation of mRNA molecules induced by viral miRNAs. It is possible that 
the degradation of viral miRNA-targeted transcripts in wt EBV-infected B cells was so 
strong that AGO2 RIP could not capture more reads of certain transcripts in wt compared 
with ΔmirALL EBV-infected B cells.  
A possible solution is to employ a method similar to AGO2 RIP-Seq that is less 
dependent on relative transcript levels. Such methods are available and described as high-
throughput sequencing of RNA isolated by crosslinking immunoprecipitation (HITS-CLIP; 
Chi et al., 2009) or individual-nucleotide resolution UV cross-linking and 
immunoprecipitation (iCLIP; König et al., 2010). These methods employ cross-linking of 
RISC and bound mRNAs using chemicals or UV such that the exact binding sites of 
miRNAs can be documented. It is still possible that extremely low expressed transcripts 
cannot be captured even by these technique, but comparing B cells infected with different 
EBV strains with these methods will provide binding sites that are present only in wt or 
+mirBART EBV-infected cells but not in ΔmirALL EBV-infected cells, which lack any viral 
miRNA. In short, utilizing cross-linking based screening approaches should increase the 
efficiency to identify direct targets of EBV miRNAs. 
 
 
EBV miRNAs can robustly and cooperatively regulate targets 
Multiple viral miRNAs redundantly control expression of important genes 
To predict the direct targets of EBV miRNAs, I combined the enrichment scores 
calculated from my AGO2 RIP-Seq analysis, the transcriptome data, and 3’-UTR reporter 
assays. As a result, I identified IL12B, PMAIP1, FCGR2B, and TGFBR2 as direct targets of 
EBV miRNAs (Fig. 7, Fig. 10, Fig. 11, Fig. 12).  
The reporter with IL12B 3’-UTR was repressed by five miRNAs, which can target at least 
six binding sites in total (Fig. 12A, Supplementary Fig. 4). It thus appears that EBV miRNAs 
can redundantly repress certain target mRNAs like IL12B. This novel finding is surprising 
 -54- 
but indicates a viral strategy directed against single-nucleotide polymorphisms (SNPs) 
within miRNA binding sites in 3’-UTRs, which may abrogate the down-regulation by 
miRNAs (Landi et al., 2008). Strangely, although IL12B is regulated by both wt EBV miRNAs 
and +mirBART EBV-unique miRNAs as discussed (Fig. 12A), IL12B did not fall into the 
intersection comparing “wt vs. ΔmirALL” and “+mirBART vs. wt” EBV-infected B cells 
according to my transcriptome analysis (Fig. 7B). In fact, only one gene was identified in 
this intersection (Fig. 7B). These observations imply that wt EBV miRNAs already suppress 
their direct targets so strongly that +mirBART EBV-unique miRNAs cannot additionally 
down-regulate transcripts like IL12B, which is possibly a sign of redundancy. 
Interestingly, miRNAs that target IL12B stem from all three miRNA-encoding regions: 
the BHRF1 cluster (miR-BHRF1-2), the BART cluster (miR-BART1, miR-BART10, and miR-
BART22), and the miR-BART2 coding region (Fig. 2, Figure 12), each of which are 
expressed from different promoters (Barth et al., 2011). This finding suggests that, even 
though the expressed miRNA may differ depending on cell types or the phase of infection 
(Cai et al., 2006; Qiu et al., 2011), IL12B will be down-regulated by miRNAs encoded by any 
of these clusters.  
Moreover, I observed the down-regulation of IL12B (coding for IL-12p40) and IL23A 
(coding for p19) at transcript levels and the reduced secretion of the heterodimeric IL-23 
cytokine (IL-12p40/p19) from EBV-infected B cells (Fig. 8B, Fig. 10, Fig. 13).  
As discussed in this section, EBV miRNAs control important targets like IL12B 
redundantly at multiple levels: (i) many viral miRNAs simultaneously control the same 
transcripts using different binding sites; (ii) viral miRNAs targeting identical mRNAs are 
encoded on different primary EBV transcripts; (iii) transcripts, whose protein products form 
multimers are down-regulated concurrently. 
 
EBV miRNAs cooperatively down-regulate LTB 
LTB is the only gene included in the intersection of the comparison “wt vs. ΔmirALL” 
and “+mirBART vs. wt” EBV-infected B cells (Fig. 7B) indicating that LTB is down-regulated 
by wt EBV miRNAs and further down-regulated by +mirBART EBV-unique miRNAs. This 
finding implies a cooperative regulation by a multitude of viral miRNAs. The in silico 
prediction with TargetScan provided two possible binding sites located on the 3’-UTR of 
LTB. Only two wt EBV miRNAs (miR-BART2 and miR-BART3) were predicted suggesting 
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that +mirBART EBV-unique miRNAs regulate LTB indirectly. LTB or lymphotoxin-β is a cell 
surface molecule, which forms a complex with lymphotoxin-α. This complex is recognized 
by lymphotoxin-βreceptor (LTβR) expressed on follicular dendritic cells or dendritic cells 
(Upadhyay and Fu, 2013), enhancing both innate and adaptive immune responses. EBV-
infected B cells will benefit from a robust and cooperative control of LTB by EBV miRNAs 
further supporting immune evasion of infected cells. 
Taken together, viral miRNAs robustly and cooperatively regulate expression of certain 
important genes like IL12B, which support the survival of EBV-infected B cell in vivo in the 
immune-competent human host. 
 
 
Conclusive Remarks 
Among the genes encoded by EBV viral miRNAs have unique features. They constitute 
a highly clustered and large repertoire, which is unique and not conserved among miRNAs 
encoded by its host or other herpes viruses. It is thus conceivable that EBV miRNAs provide 
a wide range of functions unique to this virus. Typically, the main functions of miRNAs are 
dedicated to fine-tune gene expression, but the BHRF1 cluster miRNAs have dramatic 
effects on the proliferation and survival of EBV-infected B cells in the early days of infection.  
Here, in this work, I extend these previous findings and discovered that EBV miRNAs 
have an enormous impact and control adaptive immune responses of the infected human 
host. Secretion of cytokines like IL-12 was reduced by viral miRNAs and this hampered the 
differentiation of antiviral type 1 helper T cells from naive CD4+ T cells. EBV miRNAs also 
inhibited antigen presentation of EBV-infected cells protecting them from recognition and 
killing by EBV antigen-specific CD4+ T cells. My work documented that EBV miRNAs have 
evolved to disrupt the adaptive immunity in the pre-latent phase of viral infection.
 Materials & Methods 
Nomenclature 
EBV strain 
I called the three EBV strains (mirALL, wt/B95.8 or wt, +mirBART) used in this 
dissertation as in Seto et al., 2010 for the consistency to the previous work of the group. 
Gene, transcripts, gene products, miRNA 
For calling human genes, transcripts, and gene products, I followed the guideline of the 
HUGO Gene Nomenclature Committee. I applied the same rule for EBV genes. For miRNAs, I 
followed the nomenclature used in the miRBase (Kozomara et al., 2011, www.mirbase.org). 
 
Cell culture, EBV production, and B cell infection 
Separation of human primary cells 
Human primary B and T cells were prepared from adenoidal mononuclear cells (MNC) or 
peripheral blood mononuclear cells (PBMC) by Ficoll-Hypaque gradient centrifugation. B cells, 
CD4+ T cells, and naive CD4+ T cells were separated from adenoidal MNC or PBMC using the 
MACS separator (Miltenyi Biotec) with the CD19 MicroBeads, the CD4 MicroBeads, and the 
Naive CD4+ T cell Isolation Kit II, respectively (Miltenyi Biotec).  
 
Cell lines and cell culture 
The EBV-positive Burkitt’s lymphoma cell line Raji and HEK293-based EBV producer cell 
lines (Seto et al., 2010), infected human primary B cells, and isolated T cells were maintained 
in RPMI 1640 medium (Life Technologies). HEK293T cells were maintained in DMEM medium. 
All media were supplemented with 10% FBS (Life Technologies), penicillin (100U/ml; Life 
Technologies), and streptomycin (100mg/ml; Life Technologies). Cells were cultivated at 37℃ 
in a 5% CO2 incubator.  
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Preparation of infectious EBV stocks and infection of human primary B cells 
Infectious EBV stocks were prepared as described (Seto et al., 2010). Briefly, EBV 
producer cell lines for ΔmirALL and B95.8/wt (wt), and +mirBART EBV strain were transiently 
transfected with expression plasmids encoding BZLF1 and BALF4 to induce EBV’s lytic cycle. 
I collected supernatants three days after transfection. Debrie was cleared by centrifugation at 
3000rpm for 15 minutes. Virus stocks were titered on Raji cells as previously reported (Seto et 
al., 2010). For virus infection at a multiplicity of infection of 0.1 green Raji unit per ml, primary 
B cells were cultivated with each virus stock for 18hours. After replacement with fresh 
medium, the infected cells were seeded at an initial density of 5105 cells per ml. 
 
RNA-Seq 
cDNA library preparation for RNA-Seq 
From newly infected human primary B cells of six different donors (Ad1 to Ad6), I 
extracted total RNAs at day five post infection with Trizol (Life Technologies) and Direct-Zol 
RNA MiniPrep (Zymo Research) according to the manufacturers’ protocols. The cDNA 
libraries were prepared by vertis Biotechnologie AG, Freising, Germany. Total RNAs were 
depleted of rRNAs by Ribo-Zero rRNA Removal Kit (illumina), fragmented by ultrasonication, 
and subjected to the first strand synthesis with a randomized primer. The cDNAs were PCR-
amplified and sequenced (paired-end, 50 nucleotides from both sides) with an Illumina 
HiSeq2000 instrument at the University of Wisconsin Biotechnology Center DNA Sequencing 
Facility. 
Sequencing, mapping, and data normalization 
Processing of paired-end reads (poly-A tail filtering, N-filtering, adapter removal) was done 
using FastQC and R2M (RawReadManipulator). Reads were mapped to the human genome 
(hg19 ‘core’ chromosome-set) by STAR (Dobin et al., 2012) and feature counts per transcript 
were determined using featureCounts (Liao et al., 2014) and GencodeCV19 annotations 
together with EBV’s annotation (GenBank: AJ507799). Read Counts were normalized using 
DESeq2. 
Fold change-based rank score and selecting differentially expressed genes 
Since individual differences in gene expression seem to have a stronger impact than 
transcriptome alteration induced by EBV infection (see Fig. 5A) we used a simple but efficient 
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scoring algorithm based on donor-wise fold-change based ranks. For each transcript t and 
donor k we calculate the transcript-specific rank score !! = !! !!"!!!!  where n is the number 
of all donors, m the number of all transcripts, !!" the rank of gene g in sample k. To select 
highly differentially expressed genes we transformed the rank score into a Z score, and all 
transcripts with an absolute Z score >1.6 were selected. 
KEGG pathway enrichment analysis and PCA analysis 
Enrichment of specific pathways was estimated by performing a hypergeometric 
distribution test via the KEGG API Web Service. Both KEGG pathway enrichment analysis and 
PCA analysis were done using Matlab (Mathworks).  
 
AGO2 RIP-Seq 
AGO2 RIP, deep sequencing, and mapping 
1x108 EBV-infected B cells were lysed with 1ml lysis Buffer (20mM Tris (pH7.5), 150mM 
NaCl, 0.25% NP-40, 1.5mM MgCl2, 1mM DTT, 40U/ml RNAsin (Promega), EDTA-free 
Complete tablet; Roche). The supernatant of lysed sample was incubated for four hours at 
4℃ with 60μl (3 mg of 11A9) anti-AGO2 antibody provided by Elizabeth Kremmer (Rüdel et al., 
2008), which have been conjugated to MyOne Tosylactivated Dynabeads (Life Technologies). 
Dynabeads were washed three times (150mM Tris-HCl (pH7.0), 100mM Tris-HCl (pH8), 750 
mM NaCl, 0.25% NP-40, 5mM MgCl2, 1mM DTT), and co-precipitated RNA was extracted 
with Direct-Zol RNA MiniPrep (Zymo Research). In parallel, western blot analysis of the 
Dynabeads-bound AGO2 protein was performed after the last wash. Extracted RNAs were 
poly (A)-tailed, ligated to an RNA adapter at the 5’-phosphate group to facilitate Illumina 
TruSeq sequencing, and subjected to first strand synthesis with a oligo-(dT) primer. 
Subsequent PCR amplification, deep sequencing (single-ended, 50 nucleotides), and mapping 
were performed as described in the RNA-Seq section above. 
Calculating the enrichment score 
Mapped reads from AGO2 RIP-Seqs were normalized to the total number of reads in the 
samples of each donor. To quantitate the enrichment of reads at each position of the 3’-UTRs 
of interest in wt EBV compared with ΔmirALL EBV-infected B cells, we defined an enrichment 
score. First, we calculated a parameter !!" = !!"!!"!!!" ∙ !!"!"# (!!), where u is the 3’-UTR of 
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interest, p is the position within u, t and c is the normalized numbers of mapped reads in wt 
and ΔmirALL EBV-infected B cell, respectively. The max(tu) is the maximum number within tu. 
The eup was calculated for each donor and modified using Gaussian smoothing (gauss2d.m in 
Matlab). To select 3’-UTRs bound by viral miRNAs, we set the threshold as follows: 
enrichment score >0.6 for a stretch of >20 nucleotides in the 3’-UTRs in two or more donors. 
 
 
Quantification of protein levels 
ELISA 
To detect cytokine secretion from infected B cells, 1x106 cells were seeded in 6 well plates 
at four or eleven days post infection and cultivated for four additional days with cyclosporine 
(1μg/ml; Novartis). Supernatants were collected and stored at -20°C. Enzyme-linked 
immunosorbent assays (ELISAs) for interleukin-6 (IL-6), IL-10, IL12B (p40), IL-12, IL-23, and 
TNF-α were performed following the manufacturer’s protocol (Mabtech). For IL-6, IL-10, and 
TNF-α, CpG DNA was added as previously described (Iskra et al., 2010) to induce the 
secretion of cytokines from EBV-infected B cells.  
ELISAs to quantify IFN-γ levels in the co-culture experiments were performed following the 
manufacturer’s protocol (Mabtech). 
 
Western blot analysis 
Cells were lysed with RIPA buffer (50mM Tris-HCl (pH 8), 150mM NaCl, 0.1% SDS, 1% 
NP-40, 0.5% DOC) and boiled with Laemmli buffer. Proteins were separated on 10% SDS-
PAGE gels (Carl Roth) and transferred to nitrocellulose membranes (Amersham) using Mini-
PROTEAN Tetra Cell (Bio-Rad). Membranes were blocked for 30 minutes with Roti-Block (Carl 
Roth) followed by antibody incubation. Protein levels were quantitated with the Odyssey CLx 
(LI-COR) Imager. The following primary antibodies directed against human proteins were 
used: anti-human Tubulin (B-5-1-2, Santa Cruz, 1:2500), anti-human Actin (AC-74, Sigma, 
1:10000), anti-human PMAIP1 (FL-54, Santa Cruz, 1:200), and anti-human AGO2 (C34C6, Cell 
signaling, 1:500). 
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Flow cytometry of cell surface proteins 
After immunostainings with fluorophore-conjugated antibodies, single-cell suspensions 
were measured with the aid of LSRFortessa or a FACSCanto (BD) flow cytometers equipped 
with the FACSDiva software (BD Biosciences). Acquired data were analysed with the FlowJo 
software Ver. 9.8 (FlowJo). 
The following fluorophore-conjugated antibodies directed against human antigens were 
used: APC anti-human IFN-γ (4S.B3; BioLegend),	anti-CD40 PE (5c3, IgG2b; BioLegend), anti-
ICOS-L PE (2D3, IgG2b;  BioLegend), anti-PD-L1 (CD274) APC (29E.2A3, IgG2b; BioLegend), 
anti-CD86 PE (37301, IgG1; R&D Systems), anti-CD32 (FCGR2B) PE (FUN-2, IgG2b; 
BioLegend), anti-FCRL4 PE (413D12, IgG2b; BioLegend), anti-HLA-ABC APC 
(W6/32, IgG2a;  BioLegend), anti-Lambda PE (HP6054, IgG2a, ThermoFischer), anti-Kappa 
APC (HP6062, IgG3, ThermoFisher), anti-CD80 PE-Cy5 (L307.4; BD Pharmingen), anti-HLA-
DR unlabeled (L234, IgG2a;  BioLegend), anti-HLA-DQ unlabeled (SPV-L3, IgG2a ; AbD 
Serotec), anti-HLA-DP unlabeled (B7/21, IgG3; Abcam), anti-mouse F(ab')2 APC (Policlonal, 
IgG; eBioscience), isotype IgG1 PE (MOPC-21; BioLegend), isotype IgG2b PE  (MPC-11; 
BioLegend), isotype IgG2a APC (MOPC-173; BioLegend), isotype IgG2b APC (MG2b-57; 
BioLegend), isotype IgG2a PE (MOPC-173; BioLegend), isotype IgG3 APC (MG305; 
Invitrogen). 
 
 
Prediction and validation of miRNA targets 
In silico prediction of miRNA binding sites 
I performed in silico predictions of EBV miRNA binding sites on 3’-UTRs primarily with 
TargetScan6.2 (Garcia et al., 2011) and employed RNAhybrid (Rehmsmeier et al., 2004) to 
screen for 6mer binding sites (Bartel, 2009). 
Luciferase reporter assay validation 
The 3’-UTRs of IL12B (NM_002187), PMAIP1 (NM_021127.2), FCGR2B (NM_004001), and 
TGFBR2 (NM_003242) were cloned downstream of Firefly luciferase (Fluc) in the expression 
plasmid psiCHECK-2 (Promega). To construct the viral miRNA expression vectors, we cloned 
TagBFP (Evrogen) under the control of the EF1α promoter into pCDH-EF1-MCS (System 
Biosciences). Single miRNAs of interest were cloned downstream of the TagBFP-encoding 
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gene. Viral miRNAs were obtained by PCR from the p4080 plasmid (Seto et al., 2010). 50 ng 
of the psiCHECK-2 reporter and 150ng of pCDH-EF1 miRNA expresser plasmid DNAs were 
co-transfected into 1×105 HEK293T (seeded in 24-well plate on the previous day) with 0.9μl 
Metafectene Pro (Biontex). After 24 hours of transfection, the medium was discarded and 
100μl Passive Lysis Buffer (Promega) followed by the incubation for 15 minutes while shaking 
(3D Sunflower shaker, bioSan). I measured luciferase activities with the aid of the Dual-
Luciferase Assay Kit (50μl of Luciferase Assay Reagent II and Stop & Glow Buffer for each 
sample, Promega) and the Orion II Microplate Luminometer (Titertek-Berthold). The activity of 
Fluc was normalized by the activity of Renilla luciferase (Rluc) encoded in the psiCHECK-2 
reporter. We performed site-directed mutagenesis with overlapping oligo DNAs and Phusion 
polymerase (New England Biolabs, Fig. 8E). 
 
 
Co-culture experiments of naive CD4+ T cells with EBV-infected B cells 
Th1 differentiation was assessed in co-culture experiments of sorted human naive CD4+ T 
cells with autologous B cells that have been infected with EBV and cultivated for five days. 
1×105 naive CD4+ T cells stained with CellTrace Violet (Life Technologies) and 0.5 or 1×105 
infected B cells were co-cultured in 96 well plates with Dynabeads Human T-Activator 
CD3/CD28 (Life Technologies), and cultivated for 7 days following the manufacturer’s 
instructions. The neutralizing antibody against IL12B (C8.6; BioLegend) or its isotype antibody 
(MOPC-21; BioLegend) was added for certain experiments (Fig. 10D) at 5μg/ml. Cells were re-
stimulated with PMA and Ionomycin (Cell Stimulation Cocktail; eBioscience) for 5 hours and 
treated with Brefeldin A/Monensin (BioLegend) for 2.5hours prior to fixation. The Th1 
population was determined via intracellular IFN-γ staining with the FIX & PERM Cell 
Permeabilization Kit (Life Technologies) and subsequent flow cytometry analysis. Since only 
CD3/CD28-stimulated T cells will proliferate, the Th1 population was defined as IFN-γ positive 
proliferating T cells. T cells with low CellTrace Violet staining were identified to be proliferating 
cells.  
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CD4+ T cells stimulation experiments with EBV-infected B cells 
Establishment of EBV antigen-specific effector T cells and T cell clones 
Polyclonal EBV antigen-specific CD4+ T cells were established from PBMCs by CD4 
MACS and repetitive stimulations with lymphoblastoid cell lines (LCLs) as previously 
described (Adhikary et al., 2007). 
IFN-γ release from T cells recognizing EBV-infected B cells 
IFN-γ release from LCL-stimulated, EBV antigen-specific T cells (effector cells) co-cultured 
with EBV-infected B cells (target cells) was measured to assess the antigen presentation by 
infected B cells. Effector T cells and target B cells were seeded at 5x104 cell per ml (1:1 ratio, 
unless otherwise mentioned) each and co-cultured for 16hours in a 96-well plate (V bottom). 
IFN-γ levels were detected with ELISA. IFN-γ concentrations lower than 16pg/ml were 
considered to be below the detection limit (“not detected”).  
Killing of EBV-infected B cells by T cells using the calcein release assay 
Killing activity of EBV-infected B cells by EBV antigen-specific T cells was measured with 
the calcein release assay. EBV-infected B cells were purified by Ficoll-Hypaque gradient 
centrifugation and the 5x105 target cells were labeled with calcein at 0.5µg/ml. After three 
washing steps with PBS, target and effector cells (EBV-stimulated T cells) were co-cultured in 
a 96-well plate (V bottom) with different ratios in RPMI red phenol-free medium to reduce 
background signals. After four hours of co-culture, fluorescence intensities of released calcein 
were measured with the aid of the Infinite F200 PRO fluorometer (Tecan). As controls, 
spontaneous calcein release of target cells cultivated without effector cells and completely 
lysed cells (0.5% Triton-X100) were used to define the levels of no and fully lysed target cells, 
respectively.  
 
 
Statistical analysis 
I used the Prism 6.0 software (GraphPad) for all my statistical analyses. The two-tailed 
ratio T test was applied unless otherwise mentioned.
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Appendix 
Contributions 
 
Manuel Albanese (Research Unit Gene Vectors, Helmholtz Zentrum München) 
performed experiments and analysis described in the following figures: 
Figure 7B, 7C, 12, 13 
 
Jonathan Hoser and Maximilian Hastreiter (Institute of Bioinformatics and System 
Biology, Helmholtz Zentrum München) performed bioinformatical analyses that were the 
basis for the following figures: 
 Figure 1B, 1C, 2A, 2B 
 
Dominik Lutter (Institute for Diabetes and Obesity, Helmholtz Zentrum München) 
performed bioinformatical analyses that was used in the following figures and data sets: 
 Figure 3, 4A, 5A, 6A, 8 
Supplementary Figure 1, 2 
Supplementary Table 1, 2 
  
I performed all the experiments and analyses that are not mentioned above. 
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Supplementary Figure 3 AGO2 RIP-Seq analysis of PMAIP1 
AGO2 RIP-Seq analysis of B cells infected with wt EBV or ΔmirALL EBV. EBV-infected B cells were lysed and RIP-
Seq against AGO2 was performed at day five post infection. Bioinformatical analysis were performed and shown 
as in Fig. 11. The result for the 3-’UTR of PMAIP mRNA is shown. As in IL12B (Fig. 11), only two of six samples 
showed high enrichment scores.
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target 5' AGCAUGUUUGAACCUGAUACACAAUUAUGACCAGAAAAUAU 3'
           ||| |  :||               |||  |||||||||
miRNA  3'  CGUUCCCGCU               UAC  GUCUUUUAU  5'                                           
           ||| |  :||               |||  |||XXXX||
mut    5' AGCAUGUUUGAACCUGAUACACAAUUAUGACCAGUUUUUAU 3' 
target 5' GGCAGGUGGCUUCUUAACAGCCCUGUGAGAAGCAGACAGAUGCAAAGAAAAUC 3'    
           |||:| |||              |             :|||||  ||||||
miRNA  3'  CGUUC CCG              C             UUACGU  CUUUUAU 5'                                              
           |||:| |||              |             :|||||  |XXXX|
mut    5' GGCAGGUGGCUUCUUAACAGCCCUGUGAGAAGCAGACAGAUGCAAAGUUUUUC 3'
IL12B mut (BART2)
target 5' AAUAUGGCUCCAUGAAGGUGCUAC 3'   
           |:||:|||| ||:  ||||||| 
miRNA  3' CUGUAUCACC UAUCGCCACGAU  5’
           |:||:|||| ||:  |XXXX||
mut    5' AAUAUGGCUCCAUGAAGCACGUAC 3' 
IL12B mut (BART1)
target 5' UCAGCUAAU       UUAUGUAU 3'    
           ||||:|||       |||||||
miRNA  3' UGUCGGUUGAGGUACCAAUACAU  5'    
           ||||:|||       ||XXXX|
mut    5' UCAGCUAAU       UUUACAAU 3'
IL12B mut (BART10)
Supplementary Figure 4 Mutations in the 3’-UTR reporters 
Representation of mutations introduced in the 3’-UTRs in reporter vectors (see Materials & Methods). Parts of wild-
type 3’-UTR or mutated 3’-UTR with complementarities of corresponding miRNAs are shown for each mutations. 
Several mutant 3’-UTRs contain two mutations. Complementarities are based on in silico prediction using 
RNAhybrid and classified as Watson-Click (‘|’), G:U (‘:’), or non-matching due to mutations introduced (‘X’).
wt:5’ AUGGAAGACCCUUGAAAAUAAAGAAGUA 3’
      | ||  ||   : |||||||
miRNA CGUUCCCGCUUACGUCUUUUAU
      | ||  ||   :  XX|X||
mt:5’ AUGGAAGACCCUUGUCACUAAAGAAGUA 3’
target 5’ CUAUGG AAAACUGGAAAAUAACUUUGA 3‘
          | | ||  ||  ::|||||||
miRN     CGUUCCCGCUUACGUCUUUUAU
          | | ||  ||  ::|XX|X||
mut   5’  CUAUGG AAAACUGGUCACUAACUUUGA 3’
PMAIP1_mut#2PMAIP1_mut#1
target 5'  GGGCCUUCAUGCUAUUUAAAUAUUUAAGUAAUUUAUGUAU 3'
            :|||  |   |:||            |    |||||||    
miRNA  3' UGUCGGUUGA  GGUA            CC   AAUACAU  5'
            :|||  |   |:||            |    ||XXXX|    
mut    5'  GGGCCUUCAUGCUAUUUAAAUAUUUAAGUAAUUUUACAAU 3'
target 5'   GGCUGAACUAAUAAAAACUCUUCUUUGUAAU 3'    
             :||| ||:|            ||||||||
miRNA  3' UGAUGAUCUGGUACU         GAAACAUU  5'    
             :||| ||:|            ||XXXX||
mut    5'   GGCUGAACUAAUAAAAACUCUUCUAACAAAU 3'  
IL12B mut (BART22)
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Supplementary Tables 
 
The tables described below can be found in the USB flash drive accompanied with this 
dissertation. 
 
Supplementary Table 1 Consistently regulated transcripts by EBV miRNAs 
The list of transcripts identified to be differentially regulated in the three comparisons “wt vs. 
ΔmirALL”, “+mirBART vs. ΔmirALL”, and “+mirBART vs. wt” EBV-infected B cells (Fig. 7B). 
This list contains the Ensembl Transcript IDs of transcripts that were both down- or up-
regulated, corresponding gene symbols, and log2 fold changes. 
 
Supplementary Table 2 Top highly read-enriched 3’-UTRs by AGO2 RIP-Seq 
The list of transcripts identified as candidates to be bound by EBV miRNAs encoded in 
the wt EBV strain. This list contains genomic positions that showed high enrichment scores 
(Result section 4.2), the corresponding gene symbols, and the donor numbers (Ad1 to Ad6) 
that fulfilled the criteria described in the Result section 4.2. 
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